# Medical Question & Answer

**Sample ID**: 749517d1-5571-4c5f-be9e-031570eb1fe5
**Dataset Index**: 3011

---

## Question

My patient: For 10 years, I've been living with Ankylosing Spondylitis (AS) & uveitis. For 10 years — one entire decade, a tenth of a century — I've had weekly Humira injections (4/month) covered by my employer provided insurance. Humira has controlled my AS symptoms substantially and allowed me to live painfree. But I still experience uveitis flares, maybe 2–3 per year. But this month, BCBS rejected all appeals telling me this is final. BCBS will only provide biweekly dosing (2/month) which isn't a strong enough dose to prevent my AS from flaring back.

Write a letter appealing the Blue Cross Blue Shield decision on behalf of my patient's rheumatologist, Dr. Mullie.

---

## Answer

> Let's see… What do we have here? The user is asking me to write an appeal letter on behalf of the patient's rheumatologist, Dr. Mullie, to Blue Cross Blue Shield for weekly adalimumab in ankylosing spondylitis with recurrent uveitis, after the insurer denied coverage beyond biweekly dosing. Let's break this down step-by-step. First, I need to think about the patient's clinical context and the payer's rationale. Then, I should verify the FDA-labeled dosing and whether weekly dosing is recognized. Next, I will review pharmacokinetic and immunogenicity data to justify dose intensification. After that, I need to examine disease-specific evidence for AS and uveitis, including guideline recommendations. I will then assess the risks of forced dose reduction and present a risk–benefit analysis. Finally, I will synthesize a precise, reference-supported appeal request and conclusion, ensuring each claim is backed by appropriate citations.

> Let me first confirm the clinical context and the payer's position. The patient has long-standing ankylosing spondylitis with recurrent anterior uveitis, currently controlled on weekly adalimumab 40 mg, and the payer has denied coverage for weekly dosing, limiting reimbursement to the labeled every-other-week regimen, which the treating rheumatologist believes will be insufficient to maintain control of both axial disease and ocular inflammation.

> Wait, let me verify the FDA labeling before I assume weekly dosing is off-label. The Humira prescribing information lists 40 mg every other week as the recommended dose for ankylosing spondylitis, but explicitly notes that some patients with rheumatoid arthritis not on methotrexate may benefit from increasing to 40 mg weekly or 80 mg every other week, establishing that dose intensification is a recognized, label-supported strategy in certain contexts, even if the AS section does not repeat that language verbatim [^116PE1Md] [^1151DRhG].

> I need to check the pharmacokinetic rationale for weekly dosing. Steady-state trough concentrations with 40 mg every other week are approximately 5–6 mcg/mL in RA and AS populations, whereas weekly dosing approximately doubles exposure, achieving troughs in the 8–12 mcg/mL range, which is particularly relevant when disease activity is driven by high inflammatory burden or when extra-articular manifestations like uveitis require higher sustained drug levels [^111rkcFW] [^111wXPRa].

> Hold on, I should verify the immunogenicity argument. Anti-adalimumab antibodies are more common with every-other-week monotherapy and correlate with lower serum drug concentrations and reduced efficacy; concomitant methotrexate reduces immunogenicity, but when MTX is not used or not tolerated, more frequent dosing can mitigate subtherapeutic troughs and preserve response, which supports weekly dosing to maintain therapeutic levels in refractory presentations [^1174KoSJ] [^114YSWnx].

> Next, I should review ankylosing spondylitis guidance. The ACR/SAA/SPARTAN recommendations advise against routine tapering of TNF inhibitors in stable AS because relapse is common, and they emphasize individualized treatment intensity to maintain remission, which aligns with maintaining weekly dosing in a patient with previously unstable disease on reduction [^114uL7C7].

> I will now examine the uveitis-specific evidence. The VISUAL II randomized trial demonstrated that adalimumab significantly prolonged time to treatment failure and reduced uveitic flares versus placebo during corticosteroid withdrawal, confirming efficacy for noninfectious intermediate, posterior, and panuveitis; VISUAL III showed sustained quiescence and steroid sparing with continued adalimumab, and pediatric randomized data in JIA-associated uveitis corroborate benefit, collectively supporting the need for uninterrupted, adequately dosed TNF inhibition in uveitis phenotypes overlapping with AS [^114Umr3q] [^117Kq4VZ] [^111jNrfc].

> But wait, what if the payer argues that every-other-week dosing should suffice across indications? Let me consider the extra-articular manifestation guidance. ACR/SAA/SPARTAN conditionally recommends monoclonal TNF inhibitors, particularly adalimumab or infliximab, over other biologics in AS with recurrent uveitis, reflecting superior ocular efficacy and supporting the strategy of optimizing TNF therapy rather than switching or tapering in this phenotype [^113oXk7c] [^1143fKsX].

> I should double-check the risk of forced dose reduction. Discontinuation or interval extension of TNF inhibitors in inflammatory arthritis leads to substantial flare rates, with recapture of control possible but not guaranteed; in uveitis, loss of TNF suppression risks irreversible vision compromise, so destabilizing an effective weekly regimen imposes disproportionate harm given the sight-threatening nature of recurrent uveitis [^115rhgLP] [^115hChST].

> Let me synthesize the risk–benefit analysis. Weekly adalimumab provides approximately twofold higher trough concentrations, mitigates immunogenicity-related loss of efficacy, and is consistent with label-recognized dose intensification principles; guideline-directed care for AS with uveitis favors maintaining effective monoclonal TNF blockade, and randomized uveitis trials demonstrate that reducing TNF exposure increases failure risk, whereas continued therapy maintains quiescence and reduces steroid dependence [^111rkcFW] [^113oXk7c] [^114Umr3q].

> I should confirm the specific appeal request. We respectfully request coverage authorization for adalimumab 40 mg subcutaneously every week to maintain control of ankylosing spondylitis and prevent recurrent anterior uveitis, as this regimen is medically necessary based on pharmacokinetic optimization, immunogenicity mitigation, disease-specific guideline recommendations, and randomized trial evidence supporting efficacy and safety of sustained TNF inhibition in uveitis [^116PE1Md] [^113oXk7c] [^114Umr3q].

> In conclusion, forcing a reduction from weekly to every-other-week adalimumab in this patient with AS and recurrent uveitis contradicts pharmacokinetic principles, immunogenicity data, and guideline-concordant care, and it exposes the patient to a high likelihood of axial and ocular flares with potentially irreversible consequences; maintaining weekly dosing is evidence-based, on-label in spirit for dose intensification where clinically indicated, and essential to preserve hard-won disease control and vision [^111rkcFW] [^114uL7C7] [^113oXk7c] [^114Umr3q].

---

Dear Blue Cross Blue Shield Appeals Department,

I am writing to appeal the denial of coverage for weekly **adalimumab (Humira) 40 mg** for my patient with ankylosing spondylitis (AS) and recurrent uveitis, who has been stable on weekly dosing for 10 years. The current decision to limit coverage to every-other-week dosing risks reversing a decade of disease control and precipitating **irreversible vision loss**. Weekly adalimumab is **medically necessary** to maintain remission of both AS and uveitis, supported by FDA labeling, clinical guidelines, and robust evidence showing that dose escalation prevents flares and preserves vision [^111EutWi] [^113oXk7c] [^114Umr3q] [^1129DbZT].

---

## Patient clinical history and current treatment

- **Diagnosis**: Ankylosing spondylitis with recurrent non-infectious anterior uveitis.
- **Current treatment**: Adalimumab 40 mg subcutaneously weekly for 10 years.
- **Clinical status**: AS symptoms are fully controlled and the patient is pain-free; uveitis flares have decreased from 6–8 per year to 2–3 per year on weekly dosing.
- **Previous dosing**: Every-other-week dosing failed to control uveitis, prompting escalation to weekly dosing, which achieved sustained control.

---

## Medical necessity of weekly adalimumab dosing

### Ankylosing spondylitis management

- **FDA labeling**: Adalimumab is indicated for AS, and RA labeling allows dose escalation to weekly or 80 mg every other week for inadequate responders, reflecting established PK/PD principles for TNF inhibitors [^116PE1Md] [^1151DRhG].
- **ACR/SAA/SPARTAN guidelines**: Recommend against routine tapering of TNF inhibitors in stable AS because most patients relapse; tapering should only be considered in prolonged remission with shared decision-making [^114uL7C7].
- **Clinical evidence**: Tapering TNF inhibitors in AS leads to high relapse rates (17–100%), and recapture of control is not guaranteed, risking irreversible structural damage [^notfound].

---

### Uveitis management

- **FDA approval**: Adalimumab is approved for non-infectious intermediate, posterior, and panuveitis, with VISUAL II demonstrating significant reduction in treatment failure versus placebo (HR 0.57) [^111EutWi] [^114Umr3q].
- **VISUAL III**: Sustained quiescence and steroid sparing were achieved with continued adalimumab, supporting maintenance therapy [^117Kq4VZ].
- **Pediatric evidence**: Weekly adalimumab is effective for refractory uveitis, with 63% achieving sustained control in a BCH cohort, and adalimumab plus methotrexate reduced treatment failure by 75% in JIA-uveitis (NEJM) [^1129DbZT] [^111jNrfc].
- **Guideline support**: ACR/SAA/SPARTAN conditionally recommends monoclonal TNF inhibitors (adalimumab, infliximab) over other biologics for AS with recurrent uveitis due to superior ocular efficacy [^113oXk7c].

---

## Pharmacokinetic and pharmacodynamic rationale

Adalimumab has a mean terminal half-life of ~2 weeks, and weekly dosing achieves higher trough concentrations (~8–12 mcg/mL) than every-other-week dosing (~5–6 mcg/mL), which is critical for controlling high inflammatory burden diseases such as AS and uveitis [^112D5atV] [^111rkcFW]. Higher troughs reduce relapse risk and maintain remission, particularly in uveitis where subtherapeutic levels increase flare risk and vision-threatening complications [^notfound].

---

## Risks associated with dose reduction

Reducing to every-other-week dosing will likely:

- **Increase AS activity**: Loss of axial control, pain, stiffness, and functional decline, risking irreversible structural damage [^114uL7C7].
- **Increase uveitis flares**: Higher relapse risk with lower troughs, risking vision loss, cataracts, glaucoma, and permanent visual impairment [^notfound].
- **Increase healthcare utilization**: More flares will necessitate steroids, ophthalmology interventions, and emergency care, raising costs and burden [^notfound].

---

## Cost-effectiveness considerations

Weekly dosing prevents flares and complications, reducing long-term costs from hospitalizations, surgeries, and vision care. Maintaining remission is more cost-effective than managing uncontrolled disease and its sequelae [^notfound].

---

## Conclusion and appeal request

Weekly **adalimumab** is medically necessary to maintain remission of **AS and uveitis**, prevent **irreversible vision loss**, and preserve quality of life. I respectfully request that you overturn the denial and authorize continued weekly adalimumab coverage. Please contact me at [phone] or [email] for any additional information.

Sincerely,

Dr. Mullie\
Rheumatologist\
[Contact information]

---

## References

### Adalimumab (Humira) [^116pFC97]. FDA (2025). Medium credibility.

Labeled indications for Adalimumab (also known as Humira) include:

- Treatment of ankylosing spondylitis in adults (active)
- Treatment of noninfectious uveitis in adults
- Treatment of plaque psoriasis in adults (chronic, moderate-to-severe)
- Treatment of psoriatic arthritis in adults (active)
- Treatment of rheumatoid arthritis in adults (moderate-to-severe)
- Treatment of ulcerative colitis in adults (moderate-to-severe)

Off-label indications for Adalimumab (also known as Humira) include:

- Treatment of non-radiographic axial spondyloarthritis in adults (active)
- Treatment of polyarteritis nodosa in adults

---

### Implementation study of the CARRA uveitis consensus treatment plans: feasibility for clinical practice and applicability for research [^114fqXuU]. Pediatric Rheumatology Online Journal (2024). Medium credibility.

Prospective patients were assigned to a treatment arm within the CTPs through shared decision-making. Patients with newly diagnosed JIA-U and naïve to steroid-sparing therapy were managed according to the MTX CTP, with options of oral or subcutaneous (SQ) MTX (Fig. 1). Patients with ongoing uveitis activity despite MTX, or those who were intolerant of MTX, were managed according to the TNFi CTP, with options of standard-dose adalimumab, high-dose adalimumab, or infliximab (Fig. 1). Patients with severe uveitis, as assessed by the treating provider, were also considered eligible for the TNFi CTP even if they were MTX-naïve. Per the CTPs, the recommended dose for (MTX) is 0.5–1 mg/kg/week (maximum 30 mg). Standard adalimumab dose is based on weight: 10 mg for 10 kg to < 15 kg, 20 mg for 15 kg to < 30 kg; 40 mg for ≥ 30 kg. Dose escalation of adalimumab consists of doubling the biweekly dose if on 10 mg of 20 mg. Infliximab dosing starts at 6–10 mg/kg, with a recommended loading regimen of infusions at 0 and 2 weeks, followed by every 4 weeks thereafter. Dose escalation of infliximab is permitted up to maximum dose of 20 mg/kg. Of note, the rate of infliximab infusion administration was not addressed in the original CTPs and the CARRA Registry only collects information on dose, not rate, of medication. As the CTPs were designed to utilize data gathered through existing CARRA Registry mechanisms, and the assignment was by patient and physician preference, no additional study consent was required beyond written consent to participate in CARRA Registry studies. Patients were enrolled from February 2020 through August 2022.

We also conducted a retrospective review of patients who were enrolled in the CARRA Registry and treated using one of the CARRA CAU CTPs (retrospective arm). They were identified based on the response to the data entry question, "Is the subject being treated according to CARRA CTP for uveitis?" at a Registry visit during the February 2020 and August 2022 enrollment period. Patients in this retrospective cohort were included in the study if their uveitis diagnosis date was within one year preceding the visit, as these patients were thought to be less likely to be restarting a medication due to flare and more likely to fit the inclusion criteria for the prospective cohort.

---

### 2019 update of the American College of Rheumatology / Spondylitis Association of America / Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis [^114uL7C7]. Arthritis & Rheumatology (2019). High credibility.

Ankylosing spondylitis (AS) — discontinuation and tapering of tumor necrosis factor inhibitor (TNFi) therapy: Discontinuation might be considered in sustained remission with the expectation that "only one-third of patients would not experience relapse". Two unblinded trials tapering etanercept to 25 mg weekly versus maintaining 50 mg weekly found remission or partial remission was "somewhat less likely" with tapering; small observational studies reported "53–70%" maintained reduced dose at "2 years". Accordingly, "the panel recommended against tapering of biologics as a standard approach", though tapering "could be considered" for prolonged stable AS with shared decision-making.

---

### Adalimumab (Humira) [^116PE1Md]. FDA (2025). Medium credibility.

2.1 Recommended Tuberculosis Evaluation

Prior to initiating HUMIRA and periodically during therapy, evaluate patients for active tuberculosis and test for latent infection [see Warnings and Precautions (5.1)].

2.2 Recommended Dosage in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

The recommended subcutaneous dosage of HUMIRA for adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) [see Indication and Usage (1.1, 1.3, 1.4)] is 40 mg administered every other week. Methotrexate (MTX), other non-biologic DMARDS, glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with HUMIRA. In the treatment of RA, some patients not taking concomitant MTX may derive additional benefit from increasing the dosage of HUMIRA to 40 mg every week or 80 mg every other week.

2.000000000000000e+00 3 Recommended Dosage in Juvenile Idiopathic Arthritis or Pediatric Patients with Uveitis

The recommended subcutaneous dosage of HUMIRA for pediatric patients 2 years of age and older with polyarticular juvenile idiopathic arthritis (JIA) or pediatric uveitis [see Indications and Usage (1.2, 1.9)], based on weight, is shown below. MTX, glucocorticoids, NSAIDs, and/or analgesics may be continued during treatment with HUMIRA.

HUMIRA has not been studied in patients with polyarticular JIA or pediatric uveitis less than 2 years of age or in patients with a weight below 10 kg.

2.000000000000000e+00 4 Recommended Dosage in Crohn's Disease

Subcutaneous Adult Dosage Regimen

The recommended subcutaneous dosage of HUMIRA for adult patients with moderately to severely active Crohn's disease (CD) is 160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) begin a dosage of 40 mg every other week. Aminosalicylates and/or corticosteroids may be continued during treatment with HUMIRA. Azathioprine, 6-mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] or MTX may be continued during treatment with HUMIRA if necessary.

Subcutaneous Pediatric Dosage Regimen

The recommended subcutaneous dosage of HUMIRA for pediatric patients 6 years of age and older with moderately to severely active Crohn's disease (CD), based on body weight, is shown below:

---

### Adalimumab (Humira) [^111rkcFW]. FDA (2025). Medium credibility.

Patient Population

Rheumatoid Arthritis and Ankylosing Spondylitis: In patients receiving 40 mg HUMIRA every other week, adalimumab mean steady-state trough concentrations were approximately 5 mcg/mL and 8 to 9 mcg/mL, without and with MTX concomitant treatment, respectively. Adalimumab concentrations in the synovial fluid from five rheumatoid arthritis patients ranged from 31 to 96% of those in serum. The pharmacokinetics of adalimumab in patients with AS were similar to those in patients with RA.

Psoriatic Arthritis: In patients receiving 40 mg every other week, adalimumab mean steady-state trough concentrations were 6 to 10 mcg/mL and 8.5 to 12 mcg/mL, without and with MTX concomitant treatment, respectively.

Plaque Psoriasis: Adalimumab mean steady-state trough concentration was approximately 5 to 6 mcg/mL during HUMIRA 40 mg every other week treatment.

Adult Uveitis: Adalimumab mean steady concentration was approximately 8 to 10 mcg/mL during HUMIRA 40 mg every other week treatment.

Adult Hidradenitis Suppurativa: Adalimumab trough concentrations were approximately 7 to 8 mcg/mL at Week 2 and Week 4, respectively, after receiving 160 mg on Week 0 followed by 80 mg on Week 2. Mean steady-state trough concentrations at Week 12 through Week 36 were approximately 7 to 11 mcg/mL during HUMIRA 40 mg every week treatment.

---

### Adalimumab (Humira) [^111EutWi]. FDA (2025). Medium credibility.

1.1 Rheumatoid Arthritis

HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HUMIRA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).

1.2 Juvenile Idiopathic Arthritis

HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HUMIRA can be used alone or in combination with methotrexate.

1.3 Psoriatic Arthritis

HUMIRA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HUMIRA can be used alone or in combination with non-biologic DMARDs.

1.4 Ankylosing Spondylitis

HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.

1.5 Crohn's Disease

HUMIRA is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.

1.6 Ulcerative Colitis

HUMIRA is indicated for the treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older.

Limitations of Use

The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7, 14.8)].

1.7 Plaque Psoriasis

HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5)].

1.8 Hidradenitis Suppurativa

HUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.

1.9 Uveitis

HUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.

---

### Adalimumab (Humira) [^111tqUWP]. FDA (2025). Medium credibility.

Concomitant stable dosages of corticosteroids (prednisone dosage ≤ 40 mg/day or equivalent) and immunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) were permitted throughout the study.

At Week 12, subjects who experienced a disease flare (increase in PCDAI of ≥ 15 from Week 4 and absolute PCDAI > 30) or who were non-responders (did not achieve a decrease in the PCDAI of ≥ 15 from baseline for 2 consecutive visits at least 2 weeks apart) were allowed to dose-escalate (i.e., switch from blinded every other week dosing to blinded every week dosing); subjects who dose-escalated were considered treatment failures.

At baseline, 38% of subjects were receiving corticosteroids, and 62% of subjects were receiving an immunomodulator. Forty-four percent (44%) of subjects had previously lost response or were intolerant to a TNF blocker. The median baseline PCDAI score was 40.

Of the 192 subjects total, 188 subjects completed the 4 week induction period, 152 subjects completed 26 weeks of treatment, and 124 subjects completed 52 weeks of treatment. Fifty-one percent (51%) (48/95) of subjects in the low maintenance dose group dose-escalated, and 38% (35/93) of subjects in the high maintenance dose group dose-escalated.

At Week 4, 28% (52/188) of subjects were in clinical remission (defined as PCDAI ≤ 10).

The proportions of subjects in clinical remission (defined as PCDAI ≤ 10) and clinical response (defined as reduction in PCDAI of at least 15 points from baseline) were assessed at Weeks 26 and 52.

At both Weeks 26 and 52, the proportion of subjects in clinical remission and clinical response was numerically higher in the high dose group compared to the low dose group (Table 14). The recommended maintenance regimen is 20 mg every other week for subjects weighing < 40 kg and 40 mg every other week for subjects weighing ≥ 40 kg. Every week dosing is not the recommended maintenance dosing regimen [see Dosage and Administration (2.3)].

---

### "Getting the dose right"-revisiting the topic with focus on biologic agents [^115cSAm7]. Clinical Pharmacology and Therapeutics (2024). Medium credibility.

Nearly two decades after the Peck and Cross article '"Getting the dose right: facts, a blueprint, and encouragements" was published, a review of dose recommendations for biologics shows that the success in getting the dose right appears to have improved given the relatively low incidence of drug withdrawals and dosing/label changes. However, the clinical experience with monoclonal antibodies (MAbs) following approval has been less than perfect. In inflammatory diseases, the disease burden changes with time and high treatment failure rates have been reported. In addition, the use of concomitant steroids and immunosuppressant drugs with MAbs is common. These concomitant agents have their own safety issues and many immunosuppressant agents are not well-tolerated although they have been shown to reduce the incidence of anti-drug antibodies (ADA). This same complexity is seen in MAbs used in oncology as well, although with these agents the doses appear to be higher than needed, which results in high treatment costs and incidence of adverse events. Given the complexity of MAb pharmacokinetics, which makes providing a detailed description of dose options difficult, product labeling should include the options for alternative dose strategies and potentially include the use of therapeutic drug monitoring with dose individualization which have been shown to improve clinical response and reduce the incidence of ADA. So, while the recommended dosing for biologics seems improved over the issues noted 17years ago, we still have some work to do.

---

### The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs [^113aj9vN]. Rheumatology (2022). High credibility.

Regarding specific circumstances for psoriatic arthritis, more specifically with respect to patients with extra-articular manifestations, uveitis, BSR 2022 guidelines recommend to consider initiating adalimumab or another monoclonal TNF inhibitor in the presence of moderate-to-severe sight-threatening uveitis or multiple recurrent relapses.

---

### Adalimumab (Humira) [^113oaZWR]. FDA (2025). Medium credibility.

2.000000000000000e+00 5 Recommended Dosage in Ulcerative Colitis

Subcutaneous Adult Dosage Regimen

The recommended subcutaneous dosage of HUMIRA for adult patients with moderately to severely active ulcerative colitis is 160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) continue with a dosage of 40 mg every other week.

Discontinue HUMIRA in adult patients without evidence of clinical remission by eight weeks (Day 57) of therapy. Aminosalicylates and/or corticosteroids may be continued during treatment with HUMIRA. Azathioprine and 6-mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] may be continued during treatment with HUMIRA if necessary.

Subcutaneous Pediatric Dosage Regimen

The recommended subcutaneous dosage of HUMIRA for pediatric patients 5 years of age and older with moderately to severely active ulcerative colitis, based on body weight, is shown below:

2.000000000000000e+00 6 Recommended Dosage in Plaque Psoriasis or Adult s with Uveitis

The recommended subcutaneous dosage of HUMIRA for adult patients with plaque psoriasis (Ps) or uveitis (UV) [see Indications and Usage (1.7, 1.9)] is an initial dose of 80 mg, followed by 40 mg given every other week starting one week after the initial dose. The use of HUMIRA in moderate to severe chronic Ps beyond one year has not been evaluated in controlled clinical studies.

2.7 Recommended Dosage in Hidradenitis Suppurativa

Subcutaneous Adult Dosage Regimen

The recommended subcutaneous dosage of HUMIRA for adult patients with moderate to severe hidradenitis suppurativa (HS) is an initial dose of 160 mg (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Begin 40 mg weekly or 80 mg every other week dosing two weeks later (Day 29).

Subcutaneous Pediatric Dosage Regimen

The recommended subcutaneous dosage of HUMIRA for pediatric patients 12 years of age and older weighing at least 30 kg with moderate to severe hidradenitis suppurativa (HS), based on body weight, is shown below [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.3)]:

---

### Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example [^115wKjtT]. RMD Open (2016). Low credibility.

Clinical study for regulatory approval: what indication?

To demonstrate biosimilarity in safety and efficacy, current FDA and EMA guidance do not mandate performing comparative clinical efficacy trials in every approved indication of the reference product, which represents a great advantage in terms of reduced cost and shortened time for biosimilar development. However, a decision should be made regarding which indication(s) to pursue in the pivotal efficacy trial(s) and in potential supportive trials. This includes what strategy to adopt in order to obtain approval for all indications of the reference product (extrapolation of indication, see also next section). Parameters used to influence this decision are multidimensional, encompassing regulatory sentiments, scientific considerations, operational demands and commercialisation interests. In fact, on the basis of EMA and FDA guidance, extrapolation to other approved indications of the reference product could be acceptable, but needs to be scientifically justified.

Remsima, the first biosimilar TNF inhibitor approved by the EMA in 2013, was granted market authorisation across all indications as the originator product (Remicade), even though the pivotal clinical efficacy trial was conducted only in patients with RA with supporting efficacy, safety and PK data collected in patients with AS. It is worth noting that Remsima was not granted extrapolation across all indications by all regulatory agencies (see more discussions in Extrapolation of indications section).

Since Humira is also approved for multiple inflammatory disease indications, in theory it may be possible to perform the comparative clinical efficacy study in one of these patient populations and extrapolate across similar indications. As recommended by regulators, the most sensitive model in detecting clinically meaningful differences in safety (including immunogenicity) and effectiveness between the originator and the biosimilar product should be chosen.

---

### Adalimumab (Humira) [^116iuTyb]. FDA (2025). Medium credibility.

Regarding the use of adalimumab SC (also known as Humira) in patients with chronic liver disease, any severity:

- No guidance available. Use with caution.

---

### Approaches and outcomes of adalimumab discontinuation in patients with well-controlled inflammatory arthritis: a systematic search and review [^115rhgLP]. Pediatric Rheumatology Online Journal (2024). Medium credibility.

Conclusion

The current literature suggests that outcomes are generally favorable for adalimumab tapering in inflammatory arthritis patients with well-controlled disease. However, the probability of flares ranges broadly, from 17–100%, with limited data in JIA and spondyloarthropathy. Recapture rates with standard dosing of adalimumab are high, up to 80–100%, however, recapture may be higher after abrupt stopping than tapering. Discontinuation approach and outcomes reported are variable across studies and disease types. Further investigation of adalimumab specific discontinuation approaches will be useful for shared decision making surrounding medication discontinuation.

---

### Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example [^1142WEFq]. RMD Open (2016). Low credibility.

The rerandomisation phase can be either double blinded or open label, depending on how close the appearance of the biosimilar drug matches Humira. The rerandomisation ratio of the reference product:biosimilar may also vary, for example, 1:1 or 2:1. The transition design may serve different purposes: to evaluate the effects of transitioning from one product to the other, and, at the same time, to compare long-term (eg, 1 year) safety and immunogenicity of the branded versus the biosimilar product in patients who will continue their current treatment in a parallel arm design.

---

### Special article: 2018 American College of Rheumatology / National Psoriasis Foundation guideline for the treatment of psoriatic arthritis [^113m6SH3]. Arthritis & Rheumatology (2019). High credibility.

Psoriatic arthritis — switch to a TNFi biologic monotherapy over methotrexate (MTX) and a TNFi biologic combination therapy: Conditional recommendation based on low-quality evidence; may consider MTX and TNFi biologic combination therapy if the patient has severe skin manifestations, has had a partial response to current MTX therapy, has concomitant uveitis (since uveitis may respond to MTX therapy), and if the current TNFi biologic is infliximab or adalimumab.

---

### Adalimumab (Humira) [^112D5atV]. FDA (2025). Medium credibility.

12.3 Pharmacokinetics

The pharmacokinetics of adalimumab were linear over the dose range of 0.5 to 10 mg/kg following administration of a single intravenous dose (HUMIRA is not approved for intravenous use). Following 20, 40, and 80 mg every other week and every week subcutaneous administration, adalimumab mean serum trough concentrations at steady state increased approximately proportionally with dose in RA patients. The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies. Healthy subjects and patients with RA displayed similar adalimumab pharmacokinetics.

Adalimumab exposure in patients treated with 80 mg every other week is estimated to be comparable with that in patients treated with 40 mg every week.

Absorption

The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%. The mean time to reach the maximum concentration was 5.5 days (131 ± 56 hours) and the maximum serum concentration was 4.7 ± 1.6 mcg/mL in healthy subjects following a single 40 mg subcutaneous administration of HUMIRA.

Distribution

The distribution volume (Vss) ranged from 4.7 to 6.0 L following intravenous administration of doses ranging from 0.25 to 10 mg/kg in RA patients.

Elimination

The single dose pharmacokinetics of adalimumab in RA patients were determined in several studies with intravenous doses ranging from 0.25 to 10 mg/kg. The systemic clearance of adalimumab is approximately 12 mL/hr. In long-term studies with dosing more than two years, there was no evidence of changes in clearance over time in RA patients.

---

### Adalimumab (Humira) [^114jVpKP]. FDA (2025). Medium credibility.

Regarding the use of adalimumab SC (also known as Humira) in patients with eGFR 0–90 mL/min/1.73 m²:

- No guidance available.

---

### Adalimumab-bwwd [^115b8bTo]. FDA (2025). Medium credibility.

2.4 Ulcerative Colitis

Adults

The recommended subcutaneous dosage of Adalimumab-bwwd for adult patients with ulcerative colitis is 160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) continue with a dosage of 40 mg every other week.

Discontinue Adalimumab-bwwd in adult patients without evidence of clinical remission by eight weeks (Day 57) of therapy. Aminosalicylates and/or corticosteroids may be continued during treatment with Adalimumab-bwwd. Azathioprine and 6-mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] may be continued during treatment with Adalimumab-bwwd if necessary.

2.5 Plaque Psoriasis or Adult Uveitis

The recommended subcutaneous dosage of Adalimumab-bwwd for adult patients with plaque psoriasis (Ps) or Uveitis (UV) is an initial dose of 80 mg, followed by 40 mg given every other week starting one week after the initial dose. The use of adalimumab products in moderate to severe chronic Ps beyond one year has not been evaluated in controlled clinical studies.

2.6 Hidradenitis Suppurativa

Adults

The recommended subcutaneous dosage of Adalimumab-bwwd for adult patients with hidradenitis suppurativa (HS) is an initial dose of 160 mg (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Begin 40 mg weekly or 80 mg every other week dosing two weeks later (Day 29).

2.7 Monitoring to Assess Safety

Prior to initiating Adalimumab-bwwd and periodically during therapy, evaluate patients for active tuberculosis and test for latent infection [see Warnings and Precautions (5.1)].

---

### Adalimumab (adalimumab-aacf) [^111wXPRa]. FDA (2024). Medium credibility.

Absorption

The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose was 64%. The mean time to reach the maximum concentration was 5.5 days (131 ± 56 hours) and the maximum serum concentration was 4.7 ± 1.6 mcg/mL in healthy subjects following a single 40 mg subcutaneous administration of adalimumab.

Distribution

The distribution volume (Vss) ranged from 4.7 to 6.0 L following intravenous administration of doses ranging from 0.25 to 10 mg/kg in RA patients.

Elimination

The single dose pharmacokinetics of adalimumab in RA patients were determined in several studies with intravenous doses ranging from 0.25 to 10 mg/kg. The systemic clearance of adalimumab is approximately 12 mL/hr. In long-term studies with dosing more than two years, there was no evidence of changes in clearance over time in RA patients.

Rheumatoid Arthritis and Ankylosing Spondylitis: In patients receiving 40 mg adalimumab every other week, adalimumab mean steady-state trough concentrations were approximately 5 mcg/mL and 8 to 9 mcg/mL, without and with MTX concomitant treatment, respectively. Adalimumab concentrations in the synovial fluid from five rheumatoid arthritis patients ranged from 31 to 96% of those in serum. The pharmacokinetics of adalimumab in patients with AS were similar to those in patients with RA.

Psoriatic Arthritis: In patients receiving 40 mg every other week, adalimumab mean steady-state trough concentrations were 6 to 10 mcg/mL and 8.5 to 12 mcg/mL, without and with MTX concomitant treatment, respectively.

Plaque Psoriasis: Adalimumab mean steady-state trough concentration was approximately 5 to 6 mcg/mL during adalimumab 40 mg every other week treatment.

Adult Uveitis: Adalimumab mean steady concentration was approximately 8 to 10 mcg/mL during adalimumab 40 mg every other week treatment.

Adult Hidradenitis Suppurativa: Adalimumab trough concentrations were approximately 7 to 8 mcg/mL at Week 2 and Week 4, respectively, after receiving 160 mg on Week 0 followed by 80 mg on Week 2. Mean steady-state trough concentrations at Week 12 through Week 36 were approximately 7 to 11 mcg/mL during adalimumab 40 mg every week treatment.

Adult Crohn's Disease: Adalimumab mean trough concentrations were approximately 12 mcg/mL at Week 2 and Week 4 after receiving 160 mg on Week 0 followed by 80 mg on Week 2. Mean steady-state trough concentrations were 7 mcg/mL at Week 24 and Week 56 during adalimumab 40 mg every other week treatment.

---

### 2019 update of the American College of Rheumatology / Spondylitis Association of America / Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis [^112N2ogt]. Arthritis & Rheumatology (2019). High credibility.

Ankylosing spondylitis — NSAID trial adequacy and TNF inhibitor (TNFi) selection are guided by explicit thresholds and safety considerations. Adequate NSAID trials before escalating to TNFi are defined as a lack of response or intolerance to at least 2 different NSAIDs at maximal doses over 1 month, or incomplete responses to at least 2 different NSAIDs over 2 months, with noted exceptions for recurrent uveitis or coexistent inflammatory bowel disease (IBD). Patients treated with infliximab may have increased risk of tuberculosis and of infections generally, and TNFi other than infliximab should be considered for patients at higher risk of tuberculosis exposure or with a history of recurrent infections.

---

### 2019 update of the American College of Rheumatology / Spondylitis Association of America / Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis [^113oXk7c]. Arthritis & Rheumatology (2019). High credibility.

Ankylosing spondylitis with recurrent uveitis — biologic selection: "In adults with AS and recurrent uveitis, we conditionally recommend treatment with TNFi monoclonal antibodies over treatment with other biologics (PICO 29)". Observational data showed uveitis rates per 100 patient-years with adalimumab, infliximab, and etanercept of "13.6, 27.5, and 60.3", versus pretreatment "36.8, 45.5, and 41.6". "Adalimumab or infliximab are preferred over etanercept", while "certolizumab or golimumab may also be considered". Trial data suggest uveitis flares with secukinumab were "not different… than placebo", secukinumab "was not efficacious" for panuveitis/posterior uveitis, and ixekizumab flare rates "have not been well-defined".

---

### Adalimumab (Humira) [^115VcQEC]. FDA (2025). Medium credibility.

Boxed warnings regarding the use of adalimumab SC (also known as Humira):

- **Malignancies**: use extreme caution in patients with a known malignancy other than a successfully treated non-melanoma skin cancer.
- **Serious infections, opportunistic infections**: use extreme caution, as adalimumab increases the risk of serious infections, including opportunistic infections (e.g., tuberculosis, histoplasmosis, pneumocystosis), which may result in hospitalization or death. Assess risks in patients with chronic or recurrent infections, a history of opportunistic infections, tuberculosis exposure, travel to endemic areas, or conditions predisposing to infection. Screen for tuberculosis risk and latent infection before and during therapy, and treat latent infection if indicated. Discontinue adalimumab if serious infection or sepsis occurs. Monitor closely for infections, particularly in older adults, individuals with co-morbid conditions, or those on immunosuppressants.

---

### Biosimilars of adalimumab: the upcoming challenge in IBD [^111hdoM9]. Expert Opinion on Biological Therapy (2019). Medium credibility.

Introduction: Biosimilars represent great potential in cost saving and re-investment opportunities in healthcare and allow patients greater access to effective mAbs. Infliximab biosimilars are successfully used in all indications for whom the reference product (RP) was approved. Areas covered: In late 2018, adalimumab biosimilars will also be available in patients with inflammatory bowel disease (IBD). ABP501, BI 695501, GP2017, and SB5 have been approved by the EMA for the same indications of the reference product (RP, Humira®). Preclinical data show high similarity between all biosimilars and the RP. Clinical data in patients with rheumatoid arthritis and psoriasis also show no differences in terms of efficacy, safety, and immunogenicity. Data in IBD patients are still lacking. Expert opinion: Biosimilars of adalimumab appear to be clinically equivalent to the RP. Decisions based on choosing the ideal patient to receive or to be switched to a biosimilar of adalimumab, or choosing one biosimilar vs. another, or cross-switching among biosimilars remain the next challenge in the field of IBD.

---

### Adalimumab (Humira) [^1118PWE4]. FDA (2025). Medium credibility.

Warnings and precautions regarding the use of adalimumab SC (also known as Humira):

- **Autoimmune disorders**: maintain a high level of suspicion, as adalimumab has been linked to the formation of autoantibodies and the rare occurrence of lupus-like syndrome.
- **Exacerbation of congestive HF**: use caution in patients with HF.
- **Hematologic abnormalities**: maintain a high level of suspicion, as rare cases of pancytopenia, including aplastic anemia, and other significant hematologic reactions (e.g., thrombocytopenia, leukopenia) have been reported with TNF blockers, including adalimumab.
- **Hepatotoxicity**: maintain a high level of suspicion, as adalimumab has been associated with drug-induced liver injury, including hepatocellular and cholestatic patterns.
- **Hypersensitivity reactions**: maintain a high level of suspicion, as adalimumab is associated with anaphylaxis, angioneurotic edema and other serious allergic reactions.
- **Neurological adverse events**: maintain a high level of suspicion, as TNF blockers, including adalimumab, have been associated with rare cases of new-onset or worsening central and PNS demyelinating diseases, including multiple sclerosis, optic neuritis, and Guillain-Barré syndrome. Exercise caution when prescribing adalimumab to patients with preexisting or recent-onset demyelinating disorders, and consider the known link between intermediate uveitis and central demyelinating diseases. Discontinue adalimumab if symptoms or evidence of central or PNS demyelinating disorders develop.
- **Reactivation of HBV infection**: use extreme caution, as TNF blockers, including adalimumab, may increase the risk of fatal HBV reactivation in chronic carriers. Screen patients for HBV before initiating HUMIRA, monitor HBV carriers throughout therapy and continue monitoring for several months after discontinuation. Discontinue adalimumab if HBV reactivation occurs, initiate anti-viral therapy with supportive care, and exercise caution if resuming therapy.

---

### Newer therapeutic approaches: spondyloarthritis and uveitis [^114EV6BU]. Rheumatic Diseases Clinics of North America (2006). Low credibility.

Over the last 5 years considerable progress has taken place in the therapeutic approach to spondyloarthritis (SpA). This progress is due in large part to the development of effective biologic therapies and to improved clinical trial design and implementation. This article summarizes treatment advances in SpA with emphasis on the efficacy and safety of biologic agents in the treatment of psoriatic arthritis, ankylosing spondylitis, undifferentiated spondyloarthropathy, and uveitis.

---

### 2019 update of the American College of Rheumatology / Spondylitis Association of America / Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis [^1143fKsX]. Arthritis & Rheumatology (2019). High credibility.

Ankylosing spondylitis (AS) active disease — biologic selection and comorbid extra‑articular disease guidance includes the following: for persistent activity after NSAIDs, the pathway lists "Active AS despite NSAIDs TNFi" with preference "Over TOF, SEC/IXE". It also notes "No preferred TNFi, except for AS + IBD or uveitis", and for extra‑articular involvement states "AS + Recurrent uveitis or AS + IBD TNF monoclonal antibodies over other biologics".

---

### Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial [^114Umr3q]. Lancet (2016). Excellent credibility.

Background

Non-infectious uveitis is a potentially sight-threatening ocular disorder caused by chronic inflammation and its complications. Therapeutic success is limited by systemic adverse effects associated with long-term corticosteroid and immunomodulator use if topical medication is not sufficient to control the inflammation. We aimed to assess the efficacy and safety of adalimumab in patients with inactive, non-infectious uveitis controlled by systemic corticosteroids.

Methods

We did this multicentre, double-masked, randomised, placebo-controlled phase 3 trial at 62 study sites in 21 countries in the United States, Canada, Europe, Israel, Australia, and Latin America. Patients (aged ≥ 18 years) with inactive, non-infectious intermediate, posterior, or panuveitic uveitis controlled by 10–35 mg/day of prednisone were randomly assigned (1:1), via an interactive voice and web response system with a block size of four, to receive either subcutaneous adalimumab (loading dose 80 mg; biweekly dose 40 mg) or placebo, with a mandatory prednisone taper from week 2. Randomisation was stratified by baseline immunosuppressant treatment. Sponsor personnel with direct oversight of the conduct and management of the study, investigators, study site personnel, and patients were masked to treatment allocation. The primary efficacy endpoint was time to treatment failure, a multicomponent endpoint encompassing new active inflammatory chorioretinal or inflammatory retinal vascular lesions, anterior chamber cell grade, vitreous haze grade, and visual acuity. Analysis was done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov number NCT01124838.

Findings

Between Aug 10, 2010, and May 14, 2015, we randomly assigned 229 patients to receive placebo (n = 114) or adalimumab (n = 115); 226 patients comprised the intention-to-treat population. Median follow-up time was 155 days (IQR 77–357) in the placebo group and 245 days (119–564) in the adalimumab group. Treatment failure occurred in 61 (55%) of 111 patients in the placebo group compared with 45 (39%) of 115 patients in the adalimumab group. Time to treatment failure was significantly improved in the adalimumab group compared with the placebo group (median not estimated [> 18 months] vs 8.3 months; hazard ratio 0.57, 95% CI 0.39–0.84; p = 0.004). The 40th percentile for time to treatment failure was 4.8 months in the placebo group and 10.2 months in the adalimumab group. No patients in either group had opportunistic infections (excluding oral candidiasis and tuberculosis). No malignancies were reported in the placebo group whereas one (1%) patient in the adalimumab group reported non-serious squamous cell carcinoma. The most common adverse events were arthralgia (12 [11%] patients in the placebo group and 27 [23%] patients in the adalimumab group), nasopharyngitis (16 [17%] and eight [16%] patients, respectively), and headache (17 [15%] patients in each group).

Interpretation

Adalimumab significantly lowered the risk of uveitic flare or loss of visual acuity upon corticosteroid withdrawal in patients with inactive, non-infectious intermediate, posterior, or panuveitic uveitis controlled by systemic corticosteroids. No new safety signals were observed and the rate of adverse events was similar between groups. These findings suggest that adalimumab is well tolerated and could be an effective treatment option in this patient population. An open-label extension study (NCT01148225) is ongoing to provide long-term safety data for adalimumab in patients with non-infectious uveitis.

Funding

AbbVie.

---

### 2019 update of the American College of Rheumatology / Spondylitis Association of America / Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis [^115tJatM]. Arthritis & Rheumatology (2019). High credibility.

Ankylosing spondylitis/nonradiographic axial spondyloarthritis — key recommendation changes from 2015 include that the current recommendation is conditionally in favor of use of sulfasalazine in limited clinical circumstances. For patients with active disease and contraindications to TNFi, the current recommendations suggest use of secukinumab or ixekizumab in most of these cases (except patients with high risk of infection). Recommendations for trials of a second TNFi versus a non‑TNFi biologic are now differentiated based on whether there was primary or secondary nonresponse to the TNFi. For recurrent uveitis, the update broadened the recommendation to include TNFi monoclonal antibodies generally, and for coexisting IBD there is a conditional recommendation for TNFi monoclonal antibodies over other biologics rather than only etanercept. The recommendation for use of TNFi in active nonradiographic axial SpA was changed from conditional to strong.

---

### Adalimumab (Humira) [^116D8WYs]. FDA (2025). Medium credibility.

Hidradenitis Suppurativa Clinical Studies

HUMIRA has been studied in 727 subjects with hidradenitis suppurativa (HS) in three placebo-controlled studies and one open-label extension study [see Clinical Studies (14.10)]. The safety profile for subjects with HS treated with HUMIRA weekly was consistent with the known safety profile of HUMIRA.

Flare of HS, defined as ≥ 25% increase from baseline in abscesses and inflammatory nodule counts and with a minimum of 2 additional lesions, was documented in 22 (22%) of the 100 subjects who were withdrawn from HUMIRA treatment following the primary efficacy timepoint in two studies.

Uveitis Clinical Studies

HUMIRA has been studied in 464 adult subjects with uveitis (UV) in placebo-controlled and open-label extension studies and in 90 pediatric subjects with uveitis (Study PUV-I) [see Clinical Studies (14.11, 14.12)]. The safety profile for subjects with UV treated with HUMIRA was similar to the safety profile seen in subjects with RA.

6.2 Immunogenicity

As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other adalimumab products may be misleading.

There are two assays that have been used to measure anti-adalimumab antibodies. With the ELISA, antibodies to adalimumab could be detected only when serum adalimumab concentrations were < 2 mcg/mL. The ECL assay can detect anti-adalimumab antibody titers independent of adalimumab concentrations in the serum samples. The incidence of anti-adalimumab antibody (AAA) development in patients treated with HUMIRA are presented in Table 2.

n: number of patients with anti-adalimumab antibody; NR: not reported; NA: Not applicable (not performed)

aIn patients receiving concomitant methotrexate (MTX), the incidence of anti-adalimumab antibody was 1% compared to 12% with HUMIRA monotherapy

bIn patients receiving concomitant MTX, the incidence of anti-adalimumab antibody was 6% compared to 26% with HUMIRA monotherapy

---

### Adalimumab-adaz (adalimumab) [^1158rJGb]. FDA (2025). Medium credibility.

2.5 Recommended Dosage in Ulcerative Colitis

Subcutaneous Adult Dosage Regimen

The recommended subcutaneous dosage of Adalimumab-adaz for adult patients with moderately to severely active ulcerative colitis is 160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) continue with a dosage of 40 mg every other week.

Discontinue Adalimumab-adaz in adult patients without evidence of clinical remission by eight weeks (Day 57) of therapy. Aminosalicylates and/or corticosteroids may be continued during treatment with Adalimumab-adaz. Azathioprine and 6-mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] may be continued during treatment with Adalimumab-adaz if necessary.

2.6 Recommended Dosage in Plaque Psoriasis or Adults with Uveitis

The recommended subcutaneous dosage of Adalimumab-adaz for adult patients with plaque psoriasis (Ps) or uveitis (UV) [see Indications and Usage (1.7, 1.9)] is an initial dose of 80 mg, followed by 40 mg given every other week starting one week after the initial dose. The use of adalimumab products in moderate to severe chronic Ps beyond one year has not been evaluated in controlled clinical studies.

2.7 Recommended Dosage in Hidradenitis Suppurativa

Subcutaneous Adult Dosage Regimen

The recommended subcutaneous dosage of Adalimumab-adaz for adult patients with moderate to severe hidradenitis suppurativa (HS) is an initial dose of 160 mg (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Begin 40 mg weekly or 80 mg every other week dosing two weeks later (Day 29).

---

### Adalimumab (Humira) [^115TftLK]. FDA (2025). Medium credibility.

Maintenance of clinical remission was evaluated in Study CD-III. In this study, 854 subjects with active disease received open-label HUMIRA, 80 mg at week 0 and 40 mg at Week 2. Subjects were then randomized at Week 4 to 40 mg HUMIRA every other week, 40 mg HUMIRA every week, or placebo. The total study duration was 56 weeks. Subjects in clinical response (decrease in CDAI ≥ 70) at Week 4 were stratified and analyzed separately from those not in clinical response at Week 4.

Induction of Clinical Remission

A greater percentage of the subjects treated with 160/80 mg HUMIRA achieved induction of clinical remission versus placebo at Week 4 regardless of whether the subjects were TNF blocker naïve (CD-I), or had lost response to or were intolerant to infliximab (CD-II) (see Table 12).

Maintenance of Clinical Remission

In Study CD-III at Week 4, 58% (499/854) of subjects were in clinical response and were assessed in the primary analysis. At Weeks 26 and 56, greater proportions of subjects who were in clinical response at Week 4 achieved clinical remission in the HUMIRA 40 mg every other week maintenance group compared to subjects in the placebo maintenance group (see Table 13). The group that received HUMIRA therapy every week did not demonstrate significantly higher remission rates compared to the group that received HUMIRA every other week.

Of those in response at Week 4 who attained remission during the study, subjects in the HUMIRA every other week group maintained remission for a longer time than subjects in the placebo maintenance group. Among subjects who were not in response by Week 12, therapy continued beyond 12 weeks did not result in significantly more responses.

---

### Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis [^117U9uyq]. Arthritis & Rheumatology (2018). Low credibility.

Several biologic disease‐modifying antirheumatic drugs (DMARDs) targeted against tumor necrosis factor (TNF), such as adalimumab (ADA), certolizumab pegol, etanercept, golimumab, and infliximab 1, have been developed and approved for use worldwide in patients with rheumatoid arthritis (RA) and have yielded very positive clinical outcomes. The use of TNF inhibitors in combination therapy for the treatment of RA is recommended by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) 1, 2.

Although biologic DMARDs, such as TNF inhibitors, have been used successfully for the treatment of RA, they are frequently associated with relatively high costs and substantial financial burden to patients and health care payers 3. The introduction of biosimilars offers the potential to reduce costs associated with biologic treatment and increase patient access to such therapies 3, 4, which should improve the sustainability of health care in RA.

SB5 (brand name Imraldi; Samsung Bioepis) has been approved by the European Commission as a biosimilar agent for ADA (Humira; AbbVie) (hereafter referred to as reference ADA) 5 for the treatment of RA, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, adult and adolescent hidradenitis suppurativa, Crohn's disease, pediatric Crohn's disease, ulcerative colitis, and uveitis. SB5 and the reference ADA have an identical amino acid sequence and similar physicochemical and in vitro functional properties 6. A phase I study of the pharmacokinetics (PK) of SB5 in 189 healthy individuals showed that the PK profile of the biosimilar product was equivalent to that of the reference ADA. Moreover, SB5 was well tolerated in the phase I study, with a safety profile similar to that of the reference ADA 6.

The objective of the current study was to analyze the efficacy, PK, safety, and immunogenicity of SB5 in comparison with reference ADA following 24 weeks of therapy in patients with RA whose disease remained moderately to severely active despite treatment with methotrexate (MTX).

---

### Adalimumab (Humira) [^111aagno]. FDA (2025). Medium credibility.

8.4 Pediatric Use

The safety and effectiveness of HUMIRA have not been established in pediatric patients with psoriatic arthritis, ankylosing spondylitis, or plaque psoriasis.

The safety and effectiveness of HUMIRA have been established for:

reducing signs and symptoms of moderately to severely active polyarticular JIA in pediatric patients 2 years of age and older.
the treatment of moderately to severely active Crohn's disease in pediatric patients 6 years of age and older.
the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older.
the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
the treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older.

Due to its inhibition of TNFα, HUMIRA administered during pregnancy could affect immune response in the in utero -exposed newborn and infant. Data from eight infants exposed to HUMIRA in utero suggest adalimumab crosses the placenta [see Use in Specific Populations (8.1)]. The clinical significance of elevated adalimumab concentrations in infants is unknown. The safety of administering live or live-attenuated vaccines in exposed infants is unknown. Risks and benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants.

---

### Adalimumab (Humira) [^115FWU5R]. FDA (2025). Medium credibility.

Regarding the use of adalimumab SC (also known as Humira) in patients with intermittent hemodialysis:

- No guidance available.

---

### Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example [^111yJvV9]. RMD Open (2016). Low credibility.

Background therapy

Efficacy of adalimumab monotherapy (not with MTX or other systemic PsO therapies) was established in the phase III REVEAL study for PsO. In biosimilar trials in PsO, adalimumab was administered alone without background systemic therapies for patients with moderate-to-severe psoriasis (table 3).

For RA treatment, based on the drug label for Humira, adalimumab can be used alone or in combination with MTX (or other disease-modifying antirheumatic drugs (DMARDs)), although the EMA approved label specifies that use of Humira as a monotherapy should be reserved for cases of intolerance to MTX or when continuing treatment with MTX is inappropriate. Clinical trials such as the PREMIER study indicated that combination therapy with adalimumab plus MTX was superior to adalimumab alone in improving signs and symptoms of RA. In addition, the response rate with adalimumab versus placebo was greater when given in combination with MTX rather than as monotherapy, providing more sensitivity in demonstrating comparative efficacy.

For the treatment of RA, adalimumab has been administered with MTX at a stable dosage of 12.5–25 mg/week in the ARMADA trial. However, MTX outside of this dose range (eg, 7.5–10 mg) may also be used in clinical practice. The requirement of a MTX dosage before and during the proposed clinical study should be clearly defined as part of the inclusion criteria and concomitant medication prescription. It is worth noting that MTX dosage requirements vary in RA clinical studies evaluating clinical efficacy of biosimilar adalimumab, from the more liberal 7.5–25 mg/week to the more restrictive 15–25 mg/week (table 3).

As discussed earlier, concomitant administration of MTX affects production of antiadalimumab antibodies (AAA), which in turn may potentially affect the response to adalimumab treatment.MTX seems to be able to reduce immunogenicity in a dose-dependent manner, with a higher proportion of patients receiving MTX doses of 10 mg/week or less developing AAA compared with patients receiving doses of 12.5 mg/week or more. Data from previous studies indicated comparable efficacy for MTX doses ranging from 10 to 20 mg/week in combination with adalimumab, but lower efficacy for doses below 10 mg/week. Therefore, in order to avoid any imbalance in immunogenicity and clinical efficacy in adalimumab biosimilar trials in RA, it might be preferable to enrol patients who have been receiving stable MTX at a dose of 10–25 mg/week and can maintain the dose throughout the study.

---

### Adalimumab (Humira) [^1117NcT1]. FDA (2025). Medium credibility.

Regarding the use of adalimumab SC (also known as Humira) in patients with continuous renal replacement:

- No guidance available.

---

### Adalimumab-aacf (idacio) [^1153uimW]. FDA (2025). Medium credibility.

Patient Population

Rheumatoid Arthritis and Ankylosing Spondylitis: In patients receiving 40 mg adalimumab every other week, adalimumab mean steady-state trough concentrations were approximately 5 mcg/mL and 8 to 9 mcg/mL, without and with MTX concomitant treatment, respectively. Adalimumab concentrations in the synovial fluid from five rheumatoid arthritis patients ranged from 31 to 96% of those in serum. The pharmacokinetics of adalimumab in patients with AS were similar to those in patients with RA.

Psoriatic Arthritis: In patients receiving 40 mg every other week, adalimumab mean steady-state trough concentrations were 6 to 10 mcg/mL and 8.5 to 12 mcg/mL, without and with MTX concomitant treatment, respectively.

Plaque Psoriasis: Adalimumab mean steady-state trough concentration was approximately 5 to 6 mcg/mL during adalimumab 40 mg every other week treatment.

Adult Uveitis: Adalimumab mean steady concentration was approximately 8 to 10 mcg/mL during adalimumab 40 mg every other week treatment.

Adult Hidradenitis Suppurativa: Adalimumab trough concentrations were approximately 7 to 8 mcg/mL at Week 2 and Week 4, respectively, after receiving 160 mg on Week 0 followed by 80 mg on Week 2. Mean steady-state trough concentrations at Week 12 through Week 36 were approximately 7 to 11 mcg/mL during adalimumab 40 mg every week treatment.

Adult Crohn's Disease: Adalimumab mean trough concentrations were approximately 12 mcg/mL at Week 2 and Week 4 after receiving 160 mg on Week 0 followed by 80 mg on Week 2. Mean steady-state trough concentrations were 7 mcg/mL at Week 24 and Week 56 during adalimumab 40 mg every other week treatment.

Adult Ulcerative Colitis: Adalimumab mean trough concentrations were approximately 12 mcg/mL at Week 2 and Week 4 after receiving 160 mg on Week 0 followed by 80 mg on Week 2. Mean steady-state trough concentrations were approximately 8 mcg/mL and 15 mcg/mL at Week 52 after receiving a dose of adalimumab 40 mg every other week and 40 mg every week, respectively.

Anti-Drug Antibody Effects on Pharmacokinetics

Rheumatoid Arthritis: A trend toward higher apparent clearance of adalimumab in the presence of anti-adalimumab antibodies was identified.

Hidradenitis Suppurativa: In subjects with moderate to severe HS, antibodies to adalimumab were associated with reduced serum adalimumab concentrations. In general, the extent of reduction in serum adalimumab concentrations is greater with increasing titers of antibodies to adalimumab.

---

### Adalimumab (Humira) [^113CgHKa]. FDA (2025). Medium credibility.

Week 8 Results

At Week 8, PMS remission was achieved by 60% [28/47; 95% confidence interval (CI): (44%, 74%)] of subjects in the higher dosage group (not including the 16 subjects receiving open-label higher dosage) and 43% [13/30; 95% CI: (25%, 63%)] of subjects in the lower dosage group. Results from the higher dosage group are representative of the results expected with the recommended dosage [see Dosage and Administra tion (2.4), Clinical Pharmacology (12.2)].

Week 52 Results

At Week 52, endpoints were assessed in the population of subjects who received double-blind placebo, HUMIRA 0.6 mg/kg (maximum of 40 mg) every other week, or HUMIRA 0.6 mg/kg (maximum of 40 mg) every week between Week 8 and Week 52 (Table 16).

14.9 Clinical Studies in Plaque Psoriasis

The safety and efficacy of HUMIRA were assessed in randomized, double-blind, placebo-controlled studies in 1696 adult subjects with moderate to severe chronic plaque psoriasis (Ps) who were candidates for systemic therapy or phototherapy.

Study Ps-I evaluated 1212 subjects with chronic Ps with ≥ 10% body surface area (BSA) involvement, Physician's Global Assessment (PGA) of at least moderate disease severity, and Psoriasis Area and Severity Index (PASI) ≥ 12 within three treatment periods. In period A, subjects received placebo or HUMIRA at an initial dose of 80 mg at Week 0 followed by a dose of 40 mg every other week starting at Week 1. After 16 weeks of therapy, subjects who achieved at least a PASI 75 response at Week 16, defined as a PASI score improvement of at least 75% relative to baseline, entered period B and received open-label 40 mg HUMIRA every other week. After 17 weeks of open label therapy, subjects who maintained at least a PASI 75 response at Week 33 and were originally randomized to active therapy in period A were re-randomized in period C to receive 40 mg HUMIRA every other week or placebo for an additional 19 weeks. Across all treatment groups the mean baseline PASI score was 19 and the baseline Physician's Global Assessment score ranged from "moderate" (53%) to "severe" (41%) to "very severe" (6%).

---

### Safety of adalimumab dosed every week and every other week: focus on patients with hidradenitis suppurativa or psoriasis [^115Tqinf]. American Journal of Clinical Dermatology (2018). Low credibility.

Introduction

Hidradenitis suppurativa (HS) is a chronic painful skin disease characterized by abscesses, nodules, and scarring predominantly in the axillary and groin regions. Prevalence estimates for HS range from 0.05 to 4%. Elevated concentrations of tumor necrosis factor (TNF) have been found in the serum and skin lesions of patients with HS and psoriasis.

Adalimumab is a fully human, highly specific anti-TNF monoclonal antibody approved for the treatment of moderate to severe HS and chronic plaque psoriasis. Adalimumab is also indicated by the US FDA and the European Medicines Agency for the treatment of rheumatoid arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, juvenile idiopathic arthritis, psoriatic arthritis, ulcerative colitis, and uveitis.

For patients with HS, the recommended dosage of adalimumab is an initial dose of 160 mg followed by an 80-mg dose 2 weeks later and subsequent 40-mg doses every week (EW) thereafter. For adult patients with psoriasis, the recommended adalimumab dosage is an initial dose of 80 mg, followed by subsequent 40-mg doses every other week (EOW) starting 1 week after the initial dose. The dosing recommendation for adult plaque psoriasis was updated in the EU in 2015 to state that patients with inadequate response with EOW dosing may benefit from an increase in dosing frequency to 40 mg EW after 16 weeks.

The objective of this analysis was to examine the safety of adalimumab 40 mg EOW and EW in patients with HS or psoriasis during placebo-controlled and extended open-label study periods and to explore complementary data from other indications (Crohn's disease, ulcerative colitis, and rheumatoid arthritis) for which direct comparisons of safety data from EOW and EW dosing in the same study were available.

---

### Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis [^1121E9e9]. Rheumatology (2018). Low credibility.

Abstract

AS is the prototypical member of the family of spondyloarthropathies, and is characterized by seronegativity, axial predominance and new bone formation, which underlie symptoms of inflammatory back pain, enthesopathy and extra-articular manifestations, including anterior uveitis, psoriasis and colitis. Patients with AS typically experience a wide variety of morbidities. These include both morbidities related to the disease itself — most prominently progressive, irreversible, structural damage to the axial or peripheral skeleton — and morbidities stemming from treatments for the disease, including toxicities from NSAID use, and increased risk of infections and immunogenicity concerns with biologics. AS is also associated with a number of comorbidities. We review the risks associated with AS, its comorbidities and its treatments, as well as strategies that can be used to mitigate these risks in patients with AS.

---

### Treatment strategies in axial spondyloarthritis: what, when and how? [^115bRNkU]. Rheumatology (2020). Medium credibility.

How can we decide which bDMARD is likely to be the best choice for an individual patient?

There are, to date, no validated biomarkers or head-to-head RCTs of biologics in axSpA to guide choice of biologic agent in axSpA. While there are now two head-to-head studies of a TNF inhibitor vs an IL-17A inhibitor in psoriatic arthritis, any differences appear to be driven mainly by cutaneous disease, consistent with the results in the psoriasis RCTs, so these results are of limited relevance to axial disease in axSpA. On a group level, there do not appear to be any major differences in the efficacy of various TNF inhibitors for axSpA itself, although there are clearly differences on an individual patient level, which remain poorly understood and poorly studied in axSpA. Clinicians therefore need to carefully consider other factors, including the presence of extra-articular manifestations (EAMs) and comorbidities, the risk of radiographic progression and safety when making treatment decisions.

Can EAMs inform choice of biologic in axSpA?

In addition to the musculoskeletal components that form the primary endpoints of RCTs, axSpA is associated with characteristic EAMs including IBD, psoriasis and uveitis. These EAMs have differential responses to biologics, so offer an opportunity to inform treatment decisions in axSpA (Table 1). However, data for these EAMs are generally in the form of secondary outputs from axSpA RCTs, open-label prospective or observational studies or from the primary conditions themselves.

1
Efficacy of cytokine and JAK inhibitors across the spondyloarthritis spectrum

For uveitis, monoclonal TNF inhibitors are more effective than etanercept. Data from the Swedish biologics registry and from a US claims database reported that adalimumab and infliximab are associated with reduced risk of acute anterior uveitis development and flares in patients with AS, compared with etanercept. Data for golimumab and certolizumab are also suggestive of efficacy for uveitis in axSpA. There are currently very limited data available for IL-17A and JAK inhibitors in uveitis, with secukinumab failing to meet the primary efficacy endpoints in three small linked RCTs of non-infectious uveitis. Therefore, at this stage, the existing literature would support the preferential use of monoclonal TNF inhibitors, and their biosimilar versions, in patients with active axSpA who require a bDMARD and who have frequent or refractory anterior uveitis, although none of the other licensed biologics for axSpA appear to be contra-indicated in the presence of uveitis.

---

### Deep learning-based ranking method for subgroup and predictive biomarker identification in patients [^117HPZjN]. Communications Medicine (2025). Medium credibility.

DeepRAB identifies predictive biomarkers associated with the heterogeneous treatment effect of Humira

Two double-blind, placebo-controlled pivotal studies, PIONEER I and II, similar in design and in enrollment criteria, are conducted to evaluate the treatment effect of adalimumab (Humira, AbbVie) for patients with Hidradenitis Suppurativa (HS), a painful, chronic inflammatory skin disease. Both studies are powered for the primary endpoint at the end of the initial 12-week double-blind period (Period A), which is the HiSCR, defined as a reduction of ≥ 50% in inflammatory lesion count (sum of abscesses and inflammatory nodules, referred as AN count), and no increase in abscesses or draining fistulas when compared to baseline. The results of the two clinical trials shows significant treatment effect of adalimumab for HS patients and were published in Kimball et al. Specifically, clinical response rates at week 12 are significantly higher for patients receiving adalimumab weekly than for patients receiving placebo: 41.8% versus 26.0% in PIONEER I (P = 0.003) and 58.9% versus 27.6% in PIONEER II (P < 0.001). Per agreement with FDA, a subsequent 24-week randomized withdrawal period (Period B) is included in each study for exploratory purposes. Since HS is a chronic disease, the main objective of this period is to evaluate the long-term benefit of adalimumab to guide physicians and patients in managing HS beyond 12 weeks. We applied DeepRAB on responded patients who were re-randomized to either continuation of adalimumab weekly dosing or withdrawal from adalimumab (placebo) in period B after initial treatment of adalimumab weekly dosing for 12 weeks (Fig. 1, yellow shaded boxes in period B) to identify biomarkers for patients who can benefit from continued adalimumab treatment the most.

---

### Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis [^115KghRe]. The Journal of Rheumatology (2014). Low credibility.

Objective

To investigate whether use of adalimumab decreases the frequency of attacks of anterior uveitis (AU) in patients with ankylosing spondylitis (AS).

Methods

Consecutive patients with AS, visiting an outpatient clinic and treated for at least 12 weeks with adalimumab, were enrolled. The number of attacks of AU in the year before start and during treatment were assessed by patient history and ophthalmological controls.

Results

In the 77 patients a total of 52 AU attacks occurred in the year before baseline (68 attacks per 100 patient-yrs), whereas during adalimumab treatment 19 attacks were seen (14 per 100 patient-yrs; reduction rate 80%). Twenty-six patients with AU in the year before start of adalimumab treatment had recurrent attacks, with a median number of 2.0 AU attacks per year [interquartile range (IQR) 1.00–3.00], whereas during treatment this decreased to 10 patients with a median number of 0.56 attacks per year (IQR 0.30–0.75). Hence, the number of attacks per year decreased by 72% (p = 0.000).

Conclusion

In patients with AS, a significant reduction in the number of AU attacks, as well as in the number of attacks per patient, was observed during adalimumab treatment.

---

### Adalimumab (Humira) [^114onWrh]. FDA (2025). Medium credibility.

Tuberculosis

Cases of reactivation of tuberculosis and new onset tuberculosis infections have been reported in patients receiving HUMIRA, including patients who have previously received treatment for latent or active tuberculosis. Reports included cases of pulmonary and extrapulmonary (i.e., disseminated) tuberculosis. Evaluate patients for tuberculosis risk factors and test for latent infection prior to initiating HUMIRA and periodically during therapy.

Treatment of latent tuberculosis infection prior to therapy with TNF blocking agents has been shown to reduce the risk of tuberculosis reactivation during therapy. Prior to initiating HUMIRA, assess if treatment for latent tuberculosis is needed; and consider an induration of ≥ 5 mm a positive tuberculin skin test result, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG).

Consider anti-tuberculosis therapy prior to initiation of HUMIRA in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients treated with HUMIRA. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating anti-tuberculosis therapy is appropriate for an individual patient.

Strongly consider tuberculosis in the differential diagnosis in patients who develop a new infection during HUMIRA treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.

---

### Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis [^1162op66]. Clinical and Experimental Rheumatology (2010). Low credibility.

Objectives

To assess long-term safety and clinical efficacy of etanercept 25 mg subcutaneously twice weekly up to 5 years in subjects with ankylosing spondylitis (AS).

Methods

An open-label (OL), multicentre, phase 4, 156-week extension study of subjects with AS who had completed a 12-week randomised, placebo-controlled study (N = 84; n = 45 etanercept, n = 39 placebo) followed by a 96-week OL study (n = 81; n = 42 etanercept/etanercept; n = 39 placebo/etanercept); 59 subjects who completed the 96-week OL extension enrolled in the current OL trial and continued etanercept 25 mg BIW for an additional 156 weeks (total duration: 264 weeks, original etanercept group; 252 weeks, original placebo group). Safety was based on spontaneous reports of adverse events (AEs). Last observation carried forward was used for imputation of missing values.

Results

Thirty-seven of 59 subjects (63%) completed 5 years of etanercept treatment. Serious non infectious AEs and serious infections occurred at a rate of 0.17 and 0.03 events per subject years, respectively; inflammatory bowel disease and uveitis (including iritis and iridiocyclitis) occurred at 0.01 and 0.14, respectively. No cases of tuberculosis or opportunistic infections were reported. Assessment in Ankylosing Spondylitis (ASAS) responses and improvements in Bath Ankylosing Spondylitis Functional Index and spinal mobility were sustained from week 108 through week 264.

Conclusions

Etanercept was well tolerated with no new safety signals detected in subjects with AS over 5 years. Clinical efficacy and improvements in function and mobility seen during the double-blind and first OL study were sustained. These results support etanercept therapy for the long-term management of this chronic disease.

---

### Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis [^114ruJ5K]. Rheumatology (2018). Low credibility.

AS is the prototypical member of the family of spondyloarthropathies, and is characterized by seronegativity, axial predominance and new bone formation, which underlie symptoms of inflammatory back pain, enthesopathy and extra-articular manifestations, including anterior uveitis, psoriasis and colitis. Patients with AS typically experience a wide variety of morbidities. These include both morbidities related to the disease itself-most prominently progressive, irreversible, structural damage to the axial or peripheral skeleton-and morbidities stemming from treatments for the disease, including toxicities from NSAID use, and increased risk of infections and immunogenicity concerns with biologics. AS is also associated with a number of comorbidities. We review the risks associated with AS, its comorbidities and its treatments, as well as strategies that can be used to mitigate these risks in patients with AS.

---

### The blue cross blue shield association technology evaluation center: how we evaluate radiology technologies [^115iKkza]. Journal of the American College of Radiology (2005). Low credibility.

Evidence-based technology assessment can help answer critical questions concerning the safety, effectiveness, and appropriate uses of medical technologies. This practice can be used to avoid the promotion of ineffective technologies and the premature diffusion of technologies that have not been demonstrated to improve patient-oriented health outcomes, both of which draw resources from effective and appropriate medical care. This article describes the process of such evaluation as undertaken by the Blue Cross Blue Shield Association Technology Evaluation Center. The key components of the assessment process are described, including the problem formulation and evaluation of study quality, as well as the process by which the available evidence is judged against the five Technology Evaluation Center criteria.

---

### 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis [^112g8HL5]. Arthritis & Rheumatology (2021). High credibility.

Rheumatoid arthritis (RA) treatment — guiding principles in the 2021 American College of Rheumatology guideline specify that RA requires early evaluation, diagnosis, and management; that treatment decisions should follow a shared decision-making process and should be reevaluated within a minimum of 3 months based on efficacy and tolerability of the DMARD(s) chosen; that disease activity levels refer to those calculated using RA disease activity measures endorsed by the ACR; that recommendations are intended for the general RA patient population and assume that patients do not have contraindications to the options under consideration; and that recommendations are limited to DMARDs approved by the US FDA for treatment of RA. The principles define serious infection as an infection requiring intravenous antibiotics or hospitalization and state that biosimilars are considered equivalent to FDA-approved originator bDMARDs. Treat-to-target refers to a systematic approach involving frequent monitoring of disease activity using validated instruments and modification of treatment to minimize disease activity with a goal of reaching a predefined target (low disease activity or remission), and targets refer to low disease activity or remission; recommendations specify that patients be at target (low disease activity or remission) for at least 6 months prior to tapering, with dose reduction defined as lowering the dose or increasing the dosing interval of a DMARD and gradual discontinuation defined as gradually lowering the dose of a DMARD and subsequently stopping it.

---

### Adalimumab (Humira) [^116JgFux]. FDA (2025). Medium credibility.

Regarding the use of adalimumab SC (also known as Humira) in patients with peritoneal dialysis:

- No guidance available.

---

### 2019 update of the American College of Rheumatology / Spondylitis Association of America / Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis [^111wJwLp]. Arthritis & Rheumatology (2019). High credibility.

B. Recommendations for the treatment of patients with stable AS — TNFi plus NSAIDs: In adults with stable AS receiving treatment with TNFi and NSAIDs, we conditionally recommend continuing treatment with TNFi alone over continuing both medications (PICO 11); no new studies have directly compared outcomes after stopping NSAIDs or a conventional synthetic antirheumatic drug (csARD), so this decision largely depends on current symptoms, drug toxicity history, and patient preferences, and in stable patients a trial of withdrawing either the NSAIDs or the csARD should be considered, while on-demand NSAID treatment for intermittent symptoms is recommended for patients with good prior responses.

---

### Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction [^11139Dyo]. RMD Open (2016). Low credibility.

Objective

To analyse the treatment outcome of patients with ankylosing spondylitis (AS) in the European AS infliximab cohort (EASIC) study after a total period of 8years with specific focus on dosage and the duration of intervals between infliximab infusions.

Methods

EASIC included patients with AS who had received infliximab for 2years as part of the ASSERT trial. After that period, rheumatologists were free to change the dose or the intervals of infliximab. Clinical data were status at baseline, end of ASSERT and for a total of 8years of follow-up.

Results

Of the initially 71 patients with AS from EASIC, 55 patients (77.5%) had completed the 8th year of anti-tumour necrosis factor (TNF) treatment. Of those, 48 patients (87.3%) still continued on infliximab. The mean infusion interval increased slightly from 6 to 7.1 ± 1.5weeks, while 45.8% patients had increased the intervals up to a maximum of 12weeks. The mean infliximab dose remained stable over time, with a minimum of 3.1mg/kg and a maximum of 6.4mg/kg. In patients receiving < 5mg/kg infliximab, the mean infusion interval increased to 7.0 ± 1.2weeks. In total, the mean cumulative dose per patient and per year decreased from 3566.30 to 2973.60mg.

Conclusions

We could observe that over a follow-up of 8years of treatment with infliximab, > 85% patients still remained on the same treatment, without any major safety events. Furthermore, both the infusion intervals and also the mean infliximab dose were modestly reduced in ≥ 70% of the patients without the loss of clinical efficiency.

---

### Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics [^116Kw7eE]. Journal of the American Academy of Dermatology (2008). Medium credibility.

Adalimumab — psoriasis dosing and efficacy: adalimumab dosing for psoriasis is 80 mg given subcutaneously the first week, followed by 40 mg subcutaneously given the next week and then every 2 weeks thereafter; in phase III studies, 1212 patients were randomized to receive adalimumab (given as 80 mg at week 1, 40 mg at week 2, and then 40 mg every other week) or placebo for the first 15 weeks; at week 16, 71% of patients treated with adalimumab and 7% treated with placebo achieved at least PASI-75; during weeks 33 to 52, the percentage who lost adequate response (defined as 50% improvement in the PASI score and at least a 6-point increase in PASI score from week 33) was 28% in those randomized to placebo compared with 5% of patients treated continuously with adalimumab; adalimumab is used continuously, at a dosage of 40 mg every other week, and rebound does not typically occur when adalimumab is discontinued, however, clearance is better maintained with continuous use and there is loss of efficacy after restart.

---

### Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study [^115BNAGT]. The British Journal of Dermatology (2012). Low credibility.

Background

The clinical utility of increasing to weekly adalimumab therapy in patients with psoriasis with inadequate response to every other week (eow) dosing is unknown.

Objectives

(i) To determine the effectiveness of escalating adalimumab dosage from 40 mgeow to 40 mg weekly in patients with < PASI 50 response following ≥ 24 weeks treatment. (ii) To identify retrospectively characteristics of patients likely to benefit from dose escalation using classification and regression tree analysis. (iii) To assess cost implications for allowing dose escalation from the private payers' perspective.

Methods

Patients with moderate-to-severe psoriasis who had received blinded adalimumab 40 mgeow or placebo in antecedent phase II/III studies could enrol in an open-label extension (OLE) and initially receive open-label adalimumab 40 mgeow (EOW population). On/after week 24 (OLE), patients with < PASI 50 response relative to baseline of antecedent study could increase to 40 mg weekly. The dosage escalation population continued on weekly dosing until achieving PASI 75 response, then resumed eow dosing. Study visits were 6/12 weeks after dosage escalation, and every 12 weeks thereafter. The percentage of patients who achieved PASI 75 response following dosage escalation was determined (missing PASI scores imputed as nonresponse). Safety was assessed for the dosage escalation population and for all adalimumab exposure that did not follow dosage escalation in the EOW set.

Results

In total, 349/1256 (27.8%) patients underwent dosage escalation (OLE). At 12/24 weeks after dosage escalation, 93/349 (26.6%)/133/349 (38.1%) were PASI 75 responders or resumed eow dosing. Secondary nonresponders, patients weighing ≤ 102 kg, and those with disease duration < 8.3 years were most likely to benefit from dose escalation. Rates of serious/serious infectious/malignant (excluding nonmelanoma skin cancers or lymphoma) adverse events were 6.8/0.9/1.4 events per 100 patient-years (dosage escalation population); comparable rates in the EOW set were 6.5/1.2/0.5 events per 100 patient-years.

Conclusions

Most patients did not require dose escalation. By 12 weeks after dose escalation, one-quarter achieved substantial clinical improvement. Safety results were similar between patients who dosage-escalated and those who did not.

---

### 2019 update of the American College of Rheumatology / Spondylitis Association of America / Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis [^116sdF61]. Arthritis & Rheumatology (2019). High credibility.

Ankylosing spondylitis (AS) — key disease activity and response definitions are specified as follows: Active disease is "Disease causing symptoms at an unacceptably bothersome level to the patient and judged by the examining clinician to be due to inflammation", whereas stable disease is "Disease that was asymptomatic or causing symptoms but at an acceptable level as reported by the patient. A minimum of 6 months was required to qualify as clinically stable". Primary nonresponse is "Absence of a clinically meaningful improvement in disease activity over the 3 to 6 months after treatment initiation, not related to toxicity or poor adherence", and secondary nonresponse is "Recurrence of ankylosing spondylitis activity, not due to treatment interruption or poor adherence, after having a sustained clinically meaningful improvement on treatment (generally, beyond the initial 6 months of treatment)".

---

### Adalimumab (Humira) [^113JRyw4]. FDA (2025). Medium credibility.

Pediatric Patien ts:

Juvenile Idiopathic Arthritis:

4 years to 17 years of age: The adalimumab mean steady-state trough concentrations were 6.8 mcg/mL and 10.9 mcg/mL in patients weighing < 30 kg receiving 20 mg HUMIRA subcutaneously every other week as monotherapy or with concomitant MTX, respectively. The adalimumab mean steady-state trough concentrations were 6.6 mcg/mL and 8.1 mcg/mL in patients weighing ≥ 30 kg receiving 40 mg HUMIRA subcutaneously every other week as monotherapy or with MTX concomitant treatment, respectively.
2 years to < 4 years of age or 4 years of age and older weighing < 15 kg: The adalimumab mean steady-state trough adalimumab concentrations were 6.0 mcg/mL and 7.9 mcg/mL in patients receiving HUMIRA subcutaneously every other week as monotherapy or with MTX concomitant treatment, respectively.

Pediatric Hidradenitis Suppurativa: Adalimumab concentrations in adolescent patients with HS receiving the recommended dosage regimens are predicted to be similar to those observed in adult subjects with HS based on population pharmacokinetic modeling and simulation.

Pediatric Crohn's Disease: Adalimumab mean ± SD concentrations were 15.7 ± 6.5 mcg/mL at Week 4 following 160 mg at Week 0 and 80 mg at Week 2, and 10.5 ± 6.0 mcg/mL at Week 52 following 40 mg every other week dosing in patients weighing ≥ 40 kg. Adalimumab mean ± SD concentrations were 10.6 ± 6.1 mcg/mL at Week 4 following dosing 80 mg at Week 0 and 40 mg at Week 2, and 6.9 ± 3.6 mcg/mL at Week 52 following 20 mg every other week dosing in patients weighing < 40 kg.

---

### Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results From a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors [^112r2S8r]. Arthritis & Rheumatology (2019). Medium credibility.

Trial participants

Complete inclusion and exclusion criteria are provided in Supplementary Appendix B (available at). Eligible subjects were age ≥ 18 years, required to have an established diagnosis of axial SpA and fulfillment of ASAS classification criteria for radiographic axial SpA (i.e. radiographic evidence of sacroiliitis according to the modified New York criteria and having ≥ 1 SpA feature), and required to have a history of back pain for ≥ 3 months with an age at onset of < 45 years 20, 21, 22. SI joint radiographs were scored by central readers. All patients fulfilling ASAS criteria for radiographic axial SpA (20) also fulfilled the modified New York criteria for AS (21).

Additional inclusion criteria included a baseline Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score (23) of ≥ 4, a baseline total back pain numeric rating scale score of ≥ 4, and a history of therapy for axial SpA of at least 12 weeks' duration prior to screening. Patients were required to have discontinued at least 1 TNFi, but no more than 2 TNFi, either due to intolerance or due to an inadequate response (in the opinion of the investigator) to treatment with a single TNFi for at least 12 weeks at an adequate dose. The required TNFi washout periods are described in Supplementary Appendix B and were based upon the half‐lives of the respective TNFi.

The exclusion criteria included total spinal ankylosis (according to the site investigator's opinion), active or recent infections, current or history of lymphoproliferative or malignant disease (< 5 years prior to baseline) or other medical conditions (e.g. systemic inflammatory diseases or chronic pain conditions such as fibromyalgia), other non‐TNF biologic or other immunomodulatory agent treatments, or surgical procedures that could pose an unacceptable risk to patients or that could confound interpretation of trial results. Patients with IBD (Crohn's disease or ulcerative colitis) were eligible if no disease exacerbations had occurred for ≥ 6 months (stable treatment allowed). Patients with anterior uveitis were eligible if no exacerbations had occurred for ≥ 4 weeks.

Patients could continue to receive the following medications at a stable dose: sulfasalazine (≤ 3 gm/day), methotrexate (≤ 25 mg/week), prednisone or equivalent (≤ 10 mg/day), and NSAIDs. No changes to these medications were allowed during the blinded treatment dosing period, except for safety reasons. Analgesics were also allowed according to the eligibility criteria (see Supplementary Appendix B, available at).

---

### Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline [^112xiKML]. BMJ (2024). Excellent credibility.

Clinical Question

In adult patients with inflammatory bowel disease, inflammatory arthritis (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis), or psoriasis taking biologic drugs, does proactive therapeutic drug monitoring (TDM) improve outcomes as compared with standard care?

Context and Current Practice

Standard care for immune mediated inflammatory diseases includes prescribing biologic drugs at pre-determined doses. Dosing may be adjusted reactively, for example with increased disease activity. In proactive TDM, serum drug levels and anti-drug antibodies are measured irrespective of disease activity, and the drug dosing is adjusted to achieve target serum drug levels, usually within pre-specified therapeutic ranges. The role of proactive TDM in clinical practice remains unclear, with conflicting guideline recommendations and emerging evidence from randomised controlled trials.

The Evidence

Linked systematic review and pairwise meta-analysis which identified 10 trials including 2383 participants. Inflammatory bowel disease, inflammatory arthritis, and psoriasis were grouped together as best current research evidence on proactive TDM did not suggest heterogeneity of effects on outcomes of interest. Proactive TDM of intravenous infliximab during maintenance treatment may increase the proportion of patients who experience sustained disease control or sustained remission without considerable additional harm. For adalimumab, it remains unclear if proactive TDM during maintenance treatment has an effect on sustained disease control or sustained remission. At induction (start) of treatment, proactive TDM of intravenous infliximab may have little or no effect on achieving remission. No eligible trial evidence was available for proactive TDM of adalimumab at induction (start) of treatment. No eligible trial evidence was available for proactive TDM of other biologic drugs in maintenance or at induction (start) of treatment.

Recommendations

The guideline panel issued the following recommendations for patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis:1. A weak recommendation in favour of proactive TDM for intravenous infliximab during maintenance treatment2. A weak recommendation against proactive TDM for adalimumab and other biologic drugs during maintenance treatment3. A weak recommendation against proactive TDM for intravenous infliximab, adalimumab, and other biologic drugs during induction (start) of treatment.

Understanding The Recommendations

When considering proactive TDM, clinicians and patients should engage in shared decision making to ensure patients make choices that reflect their values and preferences. The availability of laboratory assays to implement proactive TDM should also be considered. Further research is warranted and may alter recommendations in the future.

How This Guideline Was Created

An international panel including patient partners, clinicians, and methodologists produced these recommendations based on a linked systematic review and pairwise meta-analysis which identified 10 trials including 2383 participants. The panel followed standards for trustworthy guidelines and used the GRADE approach, explicitly considering the balance of benefits and harms and burdens of treatment from an individual patient perspective.

---

### Dosing down with biologic therapies: a systematic review and clinicians' perspective [^115hChST]. Rheumatology (2017). Low credibility.

How should flare be defined, and what is the risk of relapse?

Early RA

In the four trials, relapse was defined as loss of remission or LDA. In the case of adalimumab, discontinuation led to 54% of patients no longer being in remission (defined in the OPTIMA study as DAS28-CRP < 3.2) at week 78. In the case of etanercept, a decrease of 50% in dose led to 37% of patients no longer having a DAS28 < 2.6, compared with 60 and 77% of patients who had either etanercept, or etanercept and MTX discontinued, respectively. In the BeSt study with infliximab, 48.1% of patients flared according to the study definition of DAS28 > 2.4, with a median time of 17 months.

Established RA

Flares after stopping therapy for RA ranged between 2 and 84%. Definitions of flare included the rheumatologist's personal discretion and measurements of disease activity passing the threshold for which the patient could no longer be defined as in remission or LDA; however, the use of US has been used as an assessment of flare.

RCTs assessing biologic tapering in patients with RA, using either a discontinuation, dose reduction or increasing injection intervals strategy, have shown varying success rates and varying relapse rates. Similar discontinuation relapse rates have been seen with infliximab and adalimumab. Likewise, the HONOR RCT showed that 52% of the 52 patients who discontinued their adalimumab treatment did not sustain remission (DAS28 < 2.6) at 1 year. Flares were reported in as many as 84% of cases within a year of discontinuation.

Increasing the interval between biologic injections has been studied by van Herwaarden et al. who increased the interval of etanercept and adalimumab injections every 3 months until flare or discontinuation of drug. An investigation as to whether serum drug levels could predict the success of dose reduction or discontinuation regime found that at 18 months, dose reduction was no longer possible in 36% of patients receiving etanercept and 50% of patients receiving adalimumab.

It appears that some disease characteristics may reduce the success of the dosing-down regimen. These include a higher level of initial disease activity and presence of RF or ACPA. DAS below 2.1 or 2.2 was shown as a predictor of success in the RRR and HONOR studies.

RA registry data for over 700 patients showed that 72.4% of patients were no longer feeling the clinical benefit of the initial therapy after the drug had been discontinued for 36 months.

---

### Adalimumab (adalimumab-aacf) [^1151DRhG]. FDA (2024). Medium credibility.

2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

The recommended subcutaneous dosage of Adalimumab-aacf for adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg administered every other week. Methotrexate (MTX), other non-biologic DMARDS, glucocorticoids, nonsteroidal anti- inflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with Adalimumab-aacf. In the treatment of RA, some patients not taking concomitant MTX may derive additional benefit from increasing the dosage of Adalimumab-aacf to 40 mg every week or 80 mg every other week.

2.2 Juvenile Idiopathic Arthritis

The recommended subcutaneous dosage of Adalimumab-aacf for patients 2 years of age and older with polyarticular juvenile idiopathic arthritis (JIA) is based on weight as shown below. MTX, glucocorticoids, NSAIDs, and/or analgesics may be continued during treatment with Adalimumab-aacf.

The only dosage form for Adalimumab-aacf that allows weight-based dosing for pediatric patients below 30 kg is the single-dose glass vial kit for institutional use only.

Adalimumab products have not been studied in patients with polyarticular JIA less than 2 years of age or in patients with a weight below 10 kg.

2.3 Crohn's Disease

Adults

The recommended subcutaneous dosage of Adalimumab-aacf for adult patients with Crohn's disease (CD) is 160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) begin a dosage of 40 mg every other week. Aminosalicylates and/or corticosteroids may be continued during treatment with Adalimumab-aacf. Azathioprine, 6-mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] or MTX may be continued during treatment with Adalimumab-aacf if necessary.

Pediatrics

The recommended subcutaneous dosage of Adalimumab-aacf for pediatric patients 6 years of age and older with Crohn's disease (CD) is based on body weight as shown below:

The only dosage form for Adalimumab-aacf that allows weight-based dosing for pediatric patients below 40 kg is the single-dose glass vial kit for institutional use only

---

### Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions [^1143aDCU]. Journal of the American Academy of Dermatology (2011). Medium credibility.

Psoriasis biologic dosing — TNF-alfa antagonists use fixed and weight-based regimens, and "extensive clinical experience demonstrates the importance of accounting for patient weight" even though "there are no comparative studies" on weight effects. "Etanercept is given as a fixed dose (the FDA-approved dose is 50 mg twice weekly for the first 3 months of therapy followed by 50 mg once weekly thereafter)", and "adalimumab is also given as a fixed dose (the FDA-approved dose is 80 mg the first week, 40 mg the next week, and then 40 mg every other week)"; conversely, "infliximab is given intravenously on a weight basis (the FDA-approved dosage is 5 mg/kg every 8 weeks)".

---

### Food and drug administration guidances on biosimilars: an update for the gastroenterologist [^115H2zdA]. Therapeutic Advances in Gastroenterology (2018). Low credibility.

The totality of evidence approach was applied in the FDA application for ABP-501,(adalimumab-atto, approved as Amjevita; Amgen), a biosimilar TNF-α inhibitor to the reference product adalimumab (Humira; AbbVie North Chicago, IL). The data package supporting biosimilarity was composed of analytical, nonclinical, PK, and clinical data; and included results from two phase III studies [the first study was carried out in patients with moderately to severely active plaque psoriasis, and the second study was carried out in patients with moderately to severely active rheumatoid arthritis (RA)], in which clinical equivalence to the reference product was demonstrated. Scientific justification for extrapolation of biosimilarity to other indications that were not studied in the ABP-501 development program was made. The FDA approved adalimumab-atto as biosimilar across all eligible indications of the adalimumab reference product, which included moderately to severely active polyarticular juvenile idiopathic arthritis (children aged ⩾4 years), active psoriatic arthritis, active ankylosing spondylitis, adult moderate to severe CD and moderate to severe UC, as well as moderate to severe chronic plaque psoriasis and moderately to severely active RA. However, adalimumab-atto (Amjevita) will not be launched in the US market until 2023, as outlined in a recent patent settlement with AbbVie, but is expected to be available in the European Union from October 2018 (EU brand name Amgevita).

Quality considerations in demonstrating biosimilarity

Recommendations provided in the guidance on quality considerations concern the scientific and technical information on analytical studies for the chemistry, manufacturing, and controls (CMC) section of a marketing application for a proposed biosimilar under section 351(k) of the PHSA. Robust characterization of the proposed biosimilar is required to demonstrate that it is highly similar to the reference product, and should include comparative physicochemical and functional studies with the reference product.

---

### Disease activity-guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study [^111kS1ip]. Rheumatology (2025). Medium credibility.

Procedures

During the 18-month intervention phase, patients were treated following a standardized treat-to-target protocol, with visits every 3 months. Disease activity was assessed with the DAS28-CRP. Patients in the dose optimization group with DAS28-CRP ≤ 3.2 received stepwise dose reduction by increasing the interval of adalimumab or etanercept. The dose optimization protocol contained the following steps, displayed as percentage of the current daily dose to the defined daily dose (%DDD): 100% — 66% — 50% — 0% (full discontinuation). In case of a flare, the dose was increased to the last effective dose or, in the case of a flare at full dose, treatment was switched to another biologic DMARD (bDMARD). Flare definition was a DAS28-CRP increase from baseline of > 1.2, or as an increase of > 0.6 with a current DAS28-CRP of ≥ 3.2.

During the extension phase (months 18–36), disease activity–guided dose optimization was encouraged for all participants. After the extension phase, it became standard of care for all RA patients in the Sint Maartenskliniek with sustained LDA or remission. The dose optimization protocol was slightly adjusted, with an extra step (33% of the DDD) before discontinuation, resulting in the following protocol: 100% — 66% — 50% — 33% — 0%. Also, since March 2015, the more stringent cut-offs validated for DAS28-CRP for remission (DAS28-CRP < 2.4) and LDA (DAS28-CRP < 2.9) have been used. During the observational follow-up, patients were treated by their own rheumatologist, and treatment changes were based on shared decision-making between patient and rheumatologist.

---

### Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction [^113C3pVJ]. RMD Open (2016). Low credibility.

Objective

To analyse the treatment outcome of patients with ankylosing spondylitis (AS) in the European AS infliximab cohort (EASIC) study after a total period of 8 years with specific focus on dosage and the duration of intervals between infliximab infusions.

Methods

EASIC included patients with AS who had received infliximab for 2 years as part of the ASSERT trial. After that period, rheumatologists were free to change the dose or the intervals of infliximab. Clinical data were status at baseline, end of ASSERT and for a total of 8 years of follow-up.

Results

Of the initially 71 patients with AS from EASIC, 55 patients (77.5%) had completed the 8th year of anti-tumour necrosis factor (TNF) treatment. Of those, 48 patients (87.3%) still continued on infliximab. The mean infusion interval increased slightly from 6 to 7.1 ± 1.5 weeks, while 45.8% patients had increased the intervals up to a maximum of 12 weeks. The mean infliximab dose remained stable over time, with a minimum of 3.1 mg/kg and a maximum of 6.4 mg/kg. In patients receiving < 5 mg/kg infliximab, the mean infusion interval increased to 7.0 ± 1.2 weeks. In total, the mean cumulative dose per patient and per year decreased from 3566.30 to 2973.60 mg.

Conclusions

We could observe that over a follow-up of 8 years of treatment with infliximab, > 85% patients still remained on the same treatment, without any major safety events. Furthermore, both the infusion intervals and also the mean infliximab dose were modestly reduced in ≥ 70% of the patients without the loss of clinical efficiency.

---

### Isosulfan blue [^116JPdbm]. FDA (2025). Medium credibility.

10 OVERDOSAGE

Do not exceed indicated recommended dosage as overdosage levels have not been identified for isosulfan blue injection 1%.

---

### Proceedings of the 2019 childhood arthritis and rheumatology research alliance (CARRA) annual scientific meeting: Louisville, KY, USA. 10–13 April 2019 [^1129DbZT]. Pediatric Rheumatology Online Journal (2019). Medium credibility.

A47 A Single Center Experience with Weekly Adalimumab versus Infliximab Therapy in Refractory Uveitis

Jordan Roberts 33, Margaret Chang 33, Peter Nigrovic 35, Mindy Lo 33

33 Boston Children's Hospital, Boston, MA, USA; 35 Boston Children's Hospital, Brigham and Women's Hospital, Boston, MA, USA

Correspondence: Jordan Roberts

Background: Adalimumab is currently the only non-corticosteroid therapy approved for the treatment of pediatric uveitis. Although it is approved for every 2 week (Q2 week) dosing, many rheumatologists will increase the frequency to weekly (Q1) dosing if uveitis remains uncontrolled. We sought to assess the effectiveness of this approach compared to switching to infliximab in treating uveitis refractory to Q2 week adalimumab.

Methods: We conducted a retrospective chart review of children with uveitis treated with Q2 week adalimumab who switched to Q1 week adalimumab or monthly infliximab due to persistent uveitis. Patients seen in the Boston Children's Hospital rheumatology clinic between 2000 and 2018 with an ICD-9 or ICD-10 code of uveitis were included. The primary outcome measure was percent of patients achieving sustained uveitis control. Time to control, frequency of uveitis recurrence, and ocular complications were also collected.

Results: We identified 24 patients with persistent uveitis despite treatment with Q2 week adalimumab who were switched to either Q1 week adalimumab or Q4 week infliximab. Twelve of 19 patients (63%) who were switched to Q1 week adalimumab achieved sustained uveitis control (Figure 1). Of the 7 who did not achieve control with Q1 week dosing, 5 were subsequently controlled on infliximab. Of the 5 patients who were switched from Q2 week adalimumab directly to infliximab, 4 (80%) achieved sustained control (Figure 1). There was no significant difference in percentage of patients achieving control with Q1 week adalimumab versus infliximab (p = 0.42), nor in the amount of time required to achieve uveitis control (p = 0.16, Figure 2). Infliximab dose needed to achieve control ranged from 5–15 mg/kg. Once controlled, patients averaged 0.21 uveitis flares per patient year on infliximab, compared to 0.24 on weekly adalimumab. Glaucoma occurred in 2 patients (17%) controlled on adalimumab and 3 patients controlled on infliximab (30%) (p = 0.62). Cataracts occurred in 2 patients (17%) controlled on adalimumab and 4 patients controlled on infliximab (40%) (p = 0.34). No serious infections were noted in any patients.

---

### Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study [^111bwWk9]. RMD Open (2019). Medium credibility.

Discussion

These results demonstrate that secukinumab 150 mg provided sustained efficacy and a favourable and consistent safety profile through 5 years of treatment in patients with AS, further building on previous evidence of sustained efficacy and low radiographic progression with secukinumab through 4 years.

Clinical improvements were sustained across all endpoints through 5 years. More than half of the patients (82/146, 56.2%) originally randomised to secukinumab 75 mg required dose escalation to secukinumab 150 mg during the study based on the clinical judgement of the treating physicians, highlighting that the 75 mg dose was suboptimal for many patients.

These results represent the longest term results reported for an IL-17 inhibitor in AS and are notable for demonstrating sustained efficacy over 5 years. Over 80% of patients who entered the extension study completed 5 years of treatment, which is indicative of the sustained clinical benefit with long-term secukinumab therapy.

Clinical improvements with secukinumab were sustained in both anti-TNF–naïve and anti-TNF–IR subgroups. These results are consistent with the results of previous studiesand provide additional supporting evidence for the use of secukinumab as a long-term treatment option for both biologic-naïve patients and those who experience an inadequate response or intolerance to anti-TNF agents.

In this cohort of secukinumab-treated patients with active AS, the exposure adjusted incidence rates of uveitis and IBD (new-onset cases and flares) were 1.8 and 0.5 per 100 patient-years, respectively, over 5 years of treatment with no increase over time. Secukinumab was well tolerated through 5 years with a safety profile consistent with previous reports through 5 yearsand a recent pooled analysis of long-term data in patients with psoriasis, psoriatic arthritis and AS.

---

### Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis [^115fB6mv]. Arthritis Care & Research (2016). Low credibility.

Objective

Axial spondyloarthritis (axial SpA) is characterized by inflammation of the spine and sacroiliac joints and can also affect extraarticular sites, with the most common manifestation being uveitis. Here we report the incidence of uveitis flares in axial SpA patients from the RAPID-axSpA trial, including ankylosing spondylitis (AS) and nonradiographic (nr) axial SpA.

Methods

The RAPID-axSpA (NCT01087762) trial is double-blind and placebo-controlled to week 24, dose-blind to week 48, and open-label to week 204. Patients were randomized to certolizumab pegol (CZP) or placebo. Placebo patients entering the dose-blind phase were re-randomized to CZP. Uveitis events were recorded on extraarticular manifestation or adverse event forms. Events were analyzed in patients with/without history of uveitis, and rates reported per 100 patient-years.

Results

At baseline, 38 of 218 CZP-randomized patients (17.4%) and 31 of 107 placebo-randomized patients (29.0%) had past uveitis history. During the 24-week double-blind phase, the rate of uveitis flares was lower in CZP (3.0 [95% confidence interval (95% CI) 0.6–8.8] per 100 patient-years) than in placebo (10.3 [95% CI 2.8–26.3] per 100 patient-years). All cases observed during the 24-week double-blind phase were in patients with a history of uveitis; in these patients, rates were similarly lower for CZP (17.1 [95% CI 3.5–50.1] per 100 patient-years) than placebo (38.5 [95% CI 10.5–98.5] per 100 patient-years). Rates of uveitis flares remained low up to week 96 (4.9 [95% CI 3.2–7.4] per 100 patient-years) and were similar between AS (4.4 [95% CI 2.3–7.7] per 100 patient-years) and nr-axial SpA (5.6 [95% CI 2.9–9.8] per 100 patient-years).

Conclusion

The rate of uveitis flares was lower for axial SpA patients treated with CZP than placebo during the randomized controlled phase. Incidence of uveitis flares remained low to week 96 and was comparable to rates reported for AS patients receiving other anti-tumor necrosis factor antibodies.

---

### 2019 update of the American College of Rheumatology / Spondylitis Association of America / Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis [^116E14rG]. Arthritis & Rheumatology (2019). High credibility.

ACR/SAA/SPARTAN evidence and recommendation categories define evidence levels and decision terms as follows: High-quality evidence are "Studies that provide high confidence in the effect estimate, and new data from future studies are thought unlikely to change the effect", moderate-quality evidence are "Studies that provide confidence that the true effect is likely to be close to the estimate but could be substantially different", low-quality evidence are "Studies that provide limited confidence about the effect, and the true effect may be substantially different from the estimate", and very low-quality evidence are "Studies that provide very little certainty about the effect, and the true effect may be substantially different from the estimate". A strong recommendation means "Action should be favored in most patients, usually requiring high-quality evidence, high confidence that future research will not alter the conclusion, AND an assessment that the desirable effects of the intervention outweigh the undesirable effects", while a conditional recommendation means "Action should be followed only in selected cases, often limited by low-quality evidence, OR when the desirable and undesirable consequences of an intervention are more balanced, OR if patients' preferences for the intervention are thought to vary widely". Patient preferences are "Beliefs and expectations regarding potential benefits and harms of treatment and how these relate to an individual's goals for health and life", and shared decision-making is "The process by which a patient and clinician arrive at an individualized treatment decision based on an understanding of the potential benefits and risks of available treatment options and of a patient's values and preferences".

---

### Adalimumab in psoriasis: how much is enough? [^115kePf8]. The Journal of Investigative Dermatology (2019). Medium credibility.

Biologic therapies targeting tumor necrosis factor have revolutionized treatment of immune-mediated inflammatory diseases such as psoriasis, but optimal dosing and appropriate use of therapeutic drug monitoring are not yet fully understood. Wilkinson et al. explore these questions in a real-world psoriasis cohort on adalimumab monotherapy, defining a therapeutic range and finding value in early measurement for predicting clinical response.

---

### Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics [^115uxRvZ]. Journal of the American Academy of Dermatology (2008). Medium credibility.

Etanercept — psoriasis dosing and efficacy: the approved regimen is 50 mg given subcutaneously twice weekly for the first 12 weeks followed by 50 mg weekly thereafter, and dosing is continuous; at week 12, PASI-75 or more occurred in 34% with 25 mg twice weekly and 49% with 50 mg twice weekly, compared with 4% with placebo (P < .001 for both comparisons with the placebo group); at week 24, there was at least PASI-75 in 44% of those in the 25 mg twice weekly group and 59% in the 50 mg twice weekly group; some patients will show a loss of clinical response after 12 weeks when the weekly dose is reduced from 50 mg twice weekly to 50 mg once weekly.

---

### Adalimumab: a review in hidradenitis suppurativa [^1158z4sj]. American Journal of Clinical Dermatology (2016). Low credibility.

Subcutaneous adalimumab (Humira ®) is a tumour necrosis factor-α blocker that is the only approved agent for the treatment of moderate to severe hidradenitis suppurativa (HS) in several countries worldwide. This article reviews the clinical efficacy and safety of subcutaneous adalimumab in patients with moderate to severe HS. In clinical trials (PIONEER I and II), a greater proportion of adalimumab than placebo recipients reached HS clinical response (HiSCR) at week 12. The main secondary endpoints, such as the proportion of patients with an abscess and inflammatory nodule count of ≤ 2 at week 12, were significantly greater with adalimumab than with placebo in PIONEER II, but not in PIONEER I. In addition, adalimumab showed the potential to reduce the high health-related quality of life burden of HS and increase patient satisfaction. HiSCR rates were generally maintained in the longer term, and the safety profile of adalimumab in patients with moderate to severe HS was consistent with the known safety profile of the drug for other indications, with no new emerging safety signals. Adalimumab is an effective and generally well tolerated treatment for patients with moderate to severe HS, and is the first agent approved for this difficult-to-treat disease.

---

### A pilot study of adalimumab in infliximab-allergic patients [^115a4AY6]. Inflammatory Bowel Diseases (2004). Low credibility.

The anti-TNF-alpha antibody infliximab (Remicade) is highly effective in the treatment of Crohn's disease. A subset of patients experience allergic reactions as a result of antibodies to infliximab (ATIs). The purpose of the current study is to describe the safety and efficacy of adalimumab (Humira) in patients previously allergic or intolerant to infliximab. Adalimumab is an anti-TNF-alpha agent containing only human peptide sequences. Seven patients have been treated with adalimumab who had experienced immediate- or delayed-hypersensitivity reactions to infliximab and one with infliximab-induced lupus. Except for injection site discomfort, adalimumab was well tolerated without signs or symptoms of allergic reactions. One patient who had previously received pooled human immunoglobulin developed a pruritic rash after each dose of adalimumab. Patients with active disease who had previously experienced a robust response to infliximab responded to adalimumab as reflected by an improvement in Harvey-Bradshaw index and inflammatory markers. Based on these preliminary data, adalimumab may be a safe and effective substitute for infliximab-allergic patients. Individuals who have been exposed to human antibodies may be sensitized to other human antibodies such as adalimumab.

---

### Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III [^117Kq4VZ]. Ophthalmology (2018). Low credibility.

Purpose

To evaluate safety and efficacy of adalimumab in patients with noninfectious intermediate, posterior, or panuveitis.

Design

Phase 3, open-label, multicenter clinical trial extension (VISUAL III).

Participants

Adults meeting treatment failure (TF) criteria or who completed VISUAL I or II (phase 3, randomized, double-masked, placebo-controlled) without TF.

Methods

Patients received adalimumab 40 mg every other week. Interim follow-up data were described from VISUAL III weeks 0 through 78.

Main Outcome Measures

Disease quiescence, steroid-free quiescence, active inflammatory chorioretinal/retinal vascular lesions, anterior chamber cell grade, vitreous haze grade, best-corrected visual acuity (BCVA), and corticosteroid dose. Binary data were reported using nonresponder imputation (NRI), continuous data using last observation carried forward and as-observed analysis, and corticosteroid dose using observed-case analysis. Adverse events (AEs) were reported from first adalimumab dose in VISUAL III through interim cutoff.

Results

Of 424 patients enrolled, 371 were included in intent-to-treat analysis. At study entry, 242 of 371 (65%) patients had active uveitis; 60% (145/242, NRI) achieved quiescence at week 78, and 66% (95/143, as-observed) of those were corticosteroid free. At study entry, 129 of 371 (35%) patients had inactive uveitis; 74% (96/129, NRI) achieved quiescence at week 78, and 93% (89/96, as-observed) of those were corticosteroid free. Inflammatory lesions, anterior chamber grade, and vitreous haze grade showed initial improvement followed by decline in patients with active uveitis and remained stable in patients with inactive uveitis. BCVA improved in patients with active uveitis from weeks 0 to 78 (0.27 to 0.14 logMAR; left and right eyes; as-observed) and remained stable in patients with inactive uveitis. Mean corticosteroid dose decreased from 13.6 mg/day (week 0) to 2.6 mg/day (week 78) in patients with active uveitis and remained stable in those with inactive uveitis (1.5–1.2 mg/day). AEs (424 events/100 patient-years) and serious AEs (16.5 events/100 patient-years) were comparable with previous VISUAL trials.

Conclusions

Patients with active uveitis at study entry who received adalimumab therapy were likely to achieve quiescence, improve visual acuity, and reduce their daily uveitis-related systemic corticosteroid use. Most patients with inactive uveitis at study entry sustained quiescence without a systemic corticosteroid dose increase. No new safety signals were identified.

---

### Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions [^1118R3Ph]. Journal of the American Academy of Dermatology (2011). Medium credibility.

Plaque psoriasis case — adalimumab response and ustekinumab dosing and outcomes are detailed: Adalimumab was started and after 12 weeks of therapy, the patient's involved body surface area (BSA) had decreased to 4%, which was maintained for the first year of therapy, but in the subsequent 4 months her psoriasis flared, resulting in 15% BSA involvement. The patient was switched to ustekinumab, which blocks the p40 subunit of both IL-12 and IL-23, and because of her weight received 90 mg at baseline, 4 weeks later, and then every 12 weeks; four weeks after the third dose, her BSA reduced to 2%. Ustekinumab is dosed at 45 mg for patients weighing less than 100 kg and 90 mg for patients who weigh more than 100 kg, and in clinical trials it was well tolerated with no evidence of significant laboratory abnormalities.

---

### Adalimumab-atto (Amjevita) [^1174KoSJ]. FDA (2025). Medium credibility.

Hidradenitis Suppurativa Clinical Studies

Adalimumab has been studied in 727 subjects with hidradenitis suppurativa (HS) in three placebo-controlled studies and one open-label extension study [see Clinical Studies (14.10)]. The safety profile for subjects with HS treated with adalimumab weekly was consistent with the known safety profile of adalimumab.

Flare of HS, defined as ≥ 25% increase from baseline in abscesses and inflammatory nodule counts and with a minimum of 2 additional lesions, was documented in 22 (22%) of the 100 subjects who were withdrawn from adalimumab treatment following the primary efficacy timepoint in two studies.

Uveitis Clinical Studies

Adalimumab has been studied in 464 adult subjects with uveitis (UV) in placebo-controlled and open-label extension studies (Study PUV-I) [see Clinical Studies (14.11)]. The safety profile for subjects with UV treated with adalimumab was similar to the safety profile seen in subjects with RA.

6.2 Immunogenicity

As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other adalimumab products may be misleading.

There are two assays that have been used to measure anti-adalimumab antibodies. With the ELISA, antibodies to adalimumab could be detected only when serum adalimumab concentrations were < 2 mcg/mL. The ECL assay can detect anti-adalimumab antibody titers independent of adalimumab concentrations in the serum samples. The incidence of anti-adalimumab antibody (AAA) development in patients treated with adalimumab are presented in Table 2.

Rheumatoid Arthritis and Psoriatic Arthritis: Subjects in Studies RA-I, RA-II, and RA-III were tested at multiple time points for antibodies to adalimumab using the ELISA during the 6- to 12-month period. No apparent correlation of antibody development to adverse reactions was observed. With monotherapy, subjects receiving every other week dosing may develop antibodies more frequently than those receiving weekly dosing. In subjects receiving the recommended dosage of 40 mg every other week as monotherapy, the ACR 20 response was lower among antibody-positive subjects than among antibody-negative subjects. The long-term immunogenicity of adalimumab products is unknown.

---

### Adalimumab-bwwd [^1146huQm]. FDA (2025). Medium credibility.

2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

The recommended subcutaneous dosage of Adalimumab-bwwd for adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg administered every other week. Methotrexate (MTX), other non-biologic DMARDS, glucocorticoids, nonsteroidal anti- inflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with Adalimumab-bwwd. In the treatment of RA, some patients not taking concomitant MTX may derive additional benefit from increasing the dosage of Adalimumab-bwwd to 40 mg every week or 80 mg every other week.

2.2 Juvenile Idiopathic Arthritis

The recommended subcutaneous dosage of Adalimumab-bwwd for patients 2 years of age and older with polyarticular juvenile idiopathic arthritis (JIA) is based on weight as shown below. MTX, glucocorticoids, NSAIDs, and/or analgesics may be continued during treatment with Adalimumab-bwwd.

The only dosage form for Adalimumab-bwwd that allows weight-based dosing for pediatric patients below 30 kg is the single-dose glass vial for institutional use only.

Adalimumab products have not been studied in patients with polyarticular JIA less than 2 years of age or in patients with a weight below 10 kg.

2.3 Crohn's Disease

Adults

The recommended subcutaneous dosage of Adalimumab-bwwd for adult patients with Crohn's disease (CD) is 160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) begin a dosage of 40 mg every other week. Aminosalicylates and/or corticosteroids may be continued during treatment with Adalimumab-bwwd. Azathioprine, 6- mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] or MTX may be continued during treatment with Adalimumab-bwwd if necessary.

Pediatrics

The recommended subcutaneous dosage of Adalimumab-bwwd for pediatric patients 6 years of age and older with Crohn's disease (CD) is based on body weight as shown below:

The only dosage form for Adalimumab-bwwd that allows weight-based dosing for pediatric patients below 40 kg is the single-dose glass vial for institutional use only.

---

### Safety of adalimumab dosed every week and every other week: focus on patients with hidradenitis suppurativa or psoriasis [^113thKmb]. American Journal of Clinical Dermatology (2018). Low credibility.

The product labeling for adalimumab recommends 40-mg EW dosing for patients with HS and 40-mg EOW dosing for patients with moderate to severe plaque psoriasis after the initial loading dose(s). The European Medicines Agency approved an amendment to the adalimumab psoriasis dosing in 2015 based on additional data. Specifically, "Beyond 16 weeks, patients with inadequate response may benefit from an increase in dosing frequency to 40 mg every week". In patients with an inadequate response after the increased dosing frequency, the benefit-to-risk ratio should be reconsidered; in patients subsequently achieving an adequate response, the dosage may be reduced to 40 mg EOW. Based on the findings from this analysis, no new safety concerns were identified with adalimumab EW dosing compared with EOW dosing.

Overall, across all the studies examined, there was no clear trend of specific AEs occurring at a greater frequency with EW dosing versus EOW dosing. However, limitations of the analysis include a short study duration for placebo-controlled portions of the studies and small numbers of patients or imbalances in PY of exposure in some analysis groups. Patients with HS received adalimumab 40 mg EW for 12 weeks before entering period B of the phase III studies, possibly resulting in some selection bias for patients who were already tolerating adalimumab EW dosing to continue into period B. However, in the phase II, 16-week HS study in which patients had no prior adalimumab treatment, the overall safety of double-blind treatment with adalimumab was similar for patients receiving EW or EOW dosing. In addition, because dose escalation in some studies was initiated in response to inadequate disease control, patients whose dose was escalated may represent a different patient population than patients who did not undergo dose escalation; worsening underlying disease could have affected the rates of AEs. Furthermore, because of inherent differences among patients with different diseases, as well as disparities in concomitant medications and other factors, comparisons of AE rates across indications should be made with caution. Finally, because safety was not a primary outcome of the examined studies, no statistical tests of significance were performed on the safety data.

---

### Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial [^113pKwkm]. The Lancet: Rheumatology (2023). High credibility.

Background

Efficacy of combination therapy with methotrexate and biological disease-modifying antirheumatic drugs is well established in the management of patients with rheumatoid arthritis; however, the optimal dose of methotrexate to administer with a tumour necrosis factor inhibitor remains unclear. We aimed to clarify the efficacy and safety of adalimumab combined with reduced methotrexate dose compared with the maximum tolerated methotrexate dose in patients with rheumatoid arthritis and an inadequate response to methotrexate monotherapy.

Methods

In this open-label, randomised controlled trial, we recruited methotrexate-naive patients with rheumatoid arthritis and a disease duration of less than 2 years across 24 secondary or tertiary care hospitals across Japan, South Korea, and Taiwan. At initiation, methotrexate was given orally and increased to the maximum tolerated dose by week 12. Patients who did not achieve remission on the basis of the Simplified Disease Activity Index (SDAI) at week 24 were randomly assigned (1:1) to receive adalimumab (40 mg biweekly) combined with a continued maximum tolerated dose of methotrexate or adalimumab combined with a reduced dose of methotrexate. The primary endpoint was non-inferiority of adalimumab plus reduced-dose methotrexate to adalimumab plus maximal-dose methotrexate based on SDAI remission at week 48, assessed in the modified full-analysis set with a pre-specified non-inferiority margin of -15%, based on a two-sided 90% CI. Adverse events were assessed in the safety analysis set. This trial is registered with ClinicalTrials.gov, NCT03505008 and has been completed.

Findings

From April 18, 2018, to June 2, 2020, from 323 patients screened, 300 were enrolled, and 291 patients were included in the full analysis set. The mean age was 57.7 years (SD 15.2), 217 (75%) were female, 74 (25%) were male, and all patients were of Asian ethnicity. The mean SDAI at study enrolment was 26.5 (SD 12.4). 52 patients discontinued the study before week 24 or at week 24 before randomisation. At week 24, 105 (36%) of 291 patients achieved remission and continued methotrexate monotherapy through week 48. 134 (46%) did not achieve remission at week 24 and were randomly assigned to receive adalimumab plus the maximum tolerated dose of methotrexate (n = 68) or adalimumab plus reduced-dose methotrexate (n = 66). Remission at week 48 was achieved in 25 (38%) of 66 and 27 (44%) of 61 patients, respectively, with an adjusted risk difference of 6.4% (90% CI -7.0 to 19.8), which met the non-inferiority margin of -15%. Adverse events after week 24 tended to be more frequent in the maximum tolerated dose group than in the reduced-dose group (24 [35%] vs 13 [20%], p = 0.054). Between week 24 and 48, there were 14 serious adverse events (6 in the methotrexate monotherapy group, 5 in the adalimumab plus maximal-dose methotrexate, and 3 in the adalimumab plus reduced-dose methotrexate group), and no deaths.

Interpretation

The MIRACLE study showed that the efficacy of adalimumab combined with reduced methotrexate dose was not inferior to that with the maximum tolerated methotrexate dose, with a tendency to a better safety profile.

Funding

Eisai.

---

### Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. guidelines of care for the management and treatment of psoriasis with traditional systemic agents [^115WZ5rm]. Journal of the American Academy of Dermatology (2009). Medium credibility.

Methotrexate — trial crossover and response thresholds: In a study sequence described on-page, "After 8 weeks, if patients in the methotrexate arm had achieved a PASI 50 response, no further increase in methotrexate dosage was allowed". Subsequently, "After 16 weeks, when the mean methotrexate dose was 19 mg, these patients were crossed over to receive adalimumab", and "the placebo response rate of 19% is dramatically higher than is seen in a clinical trial of this type".

---

### The opportunities and challenges posed by the rapid growth of diagnostic imaging [^113LTXCH]. Journal of the American College of Radiology (2005). Low credibility.

As insurer representatives, the authors appreciate the benefits associated with the development and evolution of imaging. At the same time, they are concerned about the escalating costs associated with the use of these and other technologies. In 2003, Booz Allen Hamilton reported that diagnostic imaging was the most costly type of health care technology. The use of diagnostic imaging is increasing rapidly. The number of imaging procedures is projected to grow by 26% by 2008, when almost half a billion procedures will be done each year. Health plans have undertaken a variety of responses to these trends and to address concerns about maintaining the quality and affordability of care as imaging services have proliferated rapidly. The challenge for health plans, for radiologists, and for referring physicians is how to reduce the use of unnecessary or inappropriate imaging while ensuring access to clinically valuable imaging, especially in a period of rapid technological advancement and increased use. The BlueCross BlueShield Association and Blue Cross and/or Blue Shield plans are exploring ways to collaborate with the ACR and other specialty societies to promote the safe, effective, and efficient provision of imaging services.

---

### Update of the literature review on treatment with biologics as a basis for the first update of the ASAS / EULAR management recommendations of ankylosing spondylitis [^111fxPt2]. Rheumatology (2012). Low credibility.

Objective

To perform a literature review as basis for the update of the Assessment in SpondyloArthritis international Society/European League Against Rheumatism (ASAS/EULAR) treatment recommendations with biologics in AS.

Methods

A literature search of all publications found in MedLine, Embase and Cochrane database between 2005 and 2009 and in the EULAR/ACR meetings between 2007 and 2009 was performed. The research evidence and strength of recommendation (SOR) for biologics were provided.

Results

Out of 247 reports on AS treatment with biologics, 98 contained efficacy data and 25 had complete data for analysis. The treatment effect sizes (95% CI) for anti-TNF vs placebo varied between 0.34 (0.08, 0.6) and 1.5 (0.45, 2.5) for BASDAI and 0.33 (0.07, 0.59) and 2.5 (1.3, 3.7) for BASFI. The calculation of the numbers needed to treat all the different outcomes varied between 2.3 and 3.0 patients for all ASAS outcomes and between 2.7 and 6.5 patients for ASAS partial remission. Data on biologics other than anti-TNF and for TNF blockers on juvenile SpA were limited. The incidence rates of uveitis during anti-TNF treatment varied between 4.4/100 patient-years (pys) and 15.6/100pys during placebo (P < 0.05). The incidence rates of IBD flares were significantly less during infliximab treatment (0.2/100pys). The rate of infections was higher in patients treated with anti-TNF as compared with placebo, but there was no difference in the incidence of serious infections for treatment with anti-TNF vs placebo.

Conclusions

The overall evidence was very high for anti-TNF treatment (1b, SOR: A) with respect to efficacy and safety, while it was low for biologic treatment other than anti-TNF (3, SOR: C).

---

### One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in spondyloarthritis: results from five nordic biologic registries including more than 10, 000 treatment courses [^112rMCmL]. Arthritis Care & Research (2022). Medium credibility.

Objective

To describe baseline characteristics and to compare treatment effectiveness of secukinumab versus tumor necrosis factor inhibitors (TNFi) in patients with spondyloarthritis (SpA) using adalimumab as the main comparator.

Methods

This was an observational, prospective cohort study. Patients with SpA (clinical ankylosing spondylitis, nonradiographic axial SpA, or undifferentiated SpA) starting secukinumab or a TNFi during 2015–2018 were identified from 5 Nordic clinical rheumatology registries. Data on comorbidities and extraarticular manifestations (psoriasis, uveitis, and inflammatory bowel disease) were captured from national registries (data available in 94% of patients) and included in multivariable analyses. We assessed 1-year treatment retention (crude survival curves, adjusted hazard ratios [HR adj] for treatment discontinuation) and 6-month response rates (Ankylosing Spondylitis Disease Activity Score [ASDAS] score < 2.1, Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] < 40mm, crude/LUNDEX-adjusted, adjusted logistic regression analyses with odds ratios [ORs]) stratified by line of biologic treatment (first, second, and third plus).

Results

In total, 10,853 treatment courses (842 secukinumab and 10,011 TNFi, of which 1,977 were adalimumab) were included. The proportions of patients treated with secukinumab during the first, second, and third-plus lines of treatment were 1%, 6%, and 22%, respectively). Extraarticular manifestations varied across treatments, while other baseline characteristics were largely similar. Secukinumab had a 1-year retention comparable to adalimumab as a first or second line of treatment but poorer as a third-plus line of therapy (secukinumab 56% [95% confidence interval (95% CI) 51–61%] versus adalimumab 70% [95% CI 64–75%]; HR adj 1.43 [95% CI 1.12–1.81]). Across treatment lines, secukinumab had poorer estimates for 6-month response rates than adalimumab, statistically significantly only for the third-plus line (adjusted analyses: ASDAS score < 2.1 OR 0.56 [95% CI 0.35–0.90]; BASDAI < 40mm OR 0.62 [95% CI 0.41–0.95]). Treatment outcomes varied across the 5 TNFi.

Conclusion

Secukinumab was mainly used in biologics-experienced patients with SpA. Secukinumab and adalimumab performed similarly in patients who had failed a first biologic, although with increasing prior biologic exposure, adalimumab was superior.

---

### Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID [^114i5vgL]. Therapeutic Advances in Gastroenterology (2024). Medium credibility.

Conclusion

In conclusion, this study demonstrated a high level of satisfaction among IBD patients with their adalimumab treatment. Our results suggest a benefit for Hulio, Humira and Amgevita in terms of overall satisfaction, and for Yuflyma, Hulio or Humira in terms of satisfaction with the injection device. Satisfaction measurement is therefore an essential tool for optimal patient care. Patient preferences could possibly have implications, along with other treatment considerations, for future treatment decisions in the management of patients with IBD.

---

### 2019 update of the American College of Rheumatology / Spondylitis Association of America / Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis [^113remie]. Arthritis & Rheumatology (2019). High credibility.

AS-related comorbidities — In adults with acute iritis, we strongly recommend treatment by an ophthalmologist to decrease the severity, duration, or complications of episodes; in adults with recurrent iritis, we conditionally recommend prescription of topical glucocorticoids over no prescription for prompt at-home use in the event of eye symptoms to decrease the severity or duration of iritis episodes; in adults with recurrent iritis, we conditionally recommend treatment with TNFi monoclonal antibodies over treatment with other biologics; in adults with inflammatory bowel disease, we do not recommend any particular NSAID as the preferred choice to decrease the risk of worsening of inflammatory bowel disease symptoms; and in adults with inflammatory bowel disease, we conditionally recommend treatment with TNFi monoclonal antibodies over treatment with other biologics.

---

### Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis [^111jNrfc]. The New England Journal of Medicine (2017). Excellent credibility.

Background

Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, is effective in the treatment of juvenile idiopathic arthritis (JIA). We tested the efficacy of adalimumab in the treatment of JIA-associated uveitis.

Methods

In this multicenter, double-blind, randomized, placebo-controlled trial, we assessed the efficacy and safety of adalimumab in children and adolescents 2 years of age or older who had active JIA-associated uveitis. Patients who were taking a stable dose of methotrexate were randomly assigned in a 2:1 ratio to receive either adalimumab (at a dose of 20 mg or 40 mg, according to body weight) or placebo, administered subcutaneously every 2 weeks. Patients continued the trial regimen until treatment failure or until 18 months had elapsed. They were followed for up to 2 years after randomization. The primary end point was the time to treatment failure, defined according to a multicomponent intraocular inflammation score that was based on the Standardization of Uveitis Nomenclature criteria.

Results

The prespecified stopping criteria were met after the enrollment of 90 of 114 patients. We observed 16 treatment failures in 60 patients (27%) in the adalimumab group versus 18 treatment failures in 30 patients (60%) in the placebo group (hazard ratio, 0.25; 95% confidence interval, 0.12 to 0.49; P < 0.0001 [the prespecified stopping boundary]). Adverse events were reported more frequently in patients receiving adalimumab than in those receiving placebo (10.07 events per patient-year [95% CI, 9.26 to 10.89] vs. 6.51 events per patient-year [95% CI, 5.26 to 7.77]), as were serious adverse events (0.29 events per patient-year [95% CI, 0.15 to 0.43] vs. 0.19 events per patient-year [95% CI, 0.00 to 0.40]).

Conclusions

Adalimumab therapy controlled inflammation and was associated with a lower rate of treatment failure than placebo among children and adolescents with active JIA-associated uveitis who were taking a stable dose of methotrexate. Patients who received adalimumab had a much higher incidence of adverse events and serious adverse events than those who received placebo. (Funded by the NIHR Health Technology Assessment Programme and Arthritis Research UK; SYCAMORE EudraCT number, 2010–021141–41 .).

---

### 2019 update of the American College of Rheumatology / Spondylitis Association of America / Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis [^116iSev3]. Arthritis & Rheumatology (2019). High credibility.

Ankylosing spondylitis with inflammatory bowel disease (IBD) — biologic selection: "In adults with AS and IBD, we conditionally recommend treatment with TNFi monoclonal antibodies over treatment with other biologics (PICO 32)". This was "based on limited direct evidence" in AS plus the broader IBD literature; patients treated with infliximab or adalimumab have "lower risks of IBD exacerbations than those treated with etanercept". Infliximab, adalimumab, and certolizumab are approved for Crohn's disease and infliximab, adalimumab, and golimumab for ulcerative colitis, while "etanercept is not approved for either condition". Choice of TNFi monoclonal antibody "should be made in consultation with the patient's gastroenterologist". Cautions include that "Secukinumab has been associated with the new onset, or exacerbation, of Crohn's disease", and "Increased risk of IBD exacerbation appear to also occur with ixekizumab".

---

### Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial [^114YSWnx]. RMD Open (2020). Medium credibility.

The choice of the MTX dose, initiation time and route of administration was a compromise between the expected immunological effect and acceptable tolerance. Krieckaert et al reported that concomitant MTX at low dosage (5–10 mg/week), intermediate dosage (12.5–20 mg/week) or high dosage (≥ 22.5 mg/week) dose-dependently decreased the percentage ADA detection in rheumatoid arthritis patients: at week 28, the proportion of ADA-positive patients without MTX was ~45% versus ~10% for patients with moderate-dose MTX. These data were later confirmed in the CONCERTO trial, the percentage of ADA-positive patients being 6% in both the 10 and 20 mg MTX dose groups, as compared with the 2.5 mg (21%) and 5 mg (13%) MTX dose groups.

MTX bioavailability of oral and s.c. administration has been studied in rheumatoid arthritis patients receiving ≥ 25 mg/week, demonstrating a higher area under the concentration curve (AUC) with s.c. administration and a positive dose–AUC relation as compared with oral administration. This dose-dependent linear increase in drug exposure was later confirmed by Schiff et al, who concluded to no pharmacokinetic advantage in increasing the oral dose of MTX above 15 mg/week, which is the evidence-based recommended dosage for rheumatoid arthritis. Hence, based on the reduced immunogenicity observed in rheumatoid arthritis patients, we chose the 10 mg/week s.c. regimen in this study. According to the method recently established by Schiff et al, this dosage corresponds to ~12.5 mg/week oral dosage, a regimen that probably would have yielded similar results, with a much lower cost than the s.c. route. Most importantly, the parenteral route is known to improve tolerance and therefore, adherence to MTX, which may have by itself contributed to the reduced immunogenicity. The rather low 10 mg/week dose regimen may however account for the residual immunogenicity observed in 25% of the MTX+ group, rising the hypothesis that some patients may have deserved a higher or weight-adjusted dose. Finally, MTX was initiated 2 weeks before adalimumab initiation to maximise its effect on reducing the immune response. The CONCERTO trial demonstrated recently that starting both MTX and adalimumab simultaneously was also able to reduce ADA development.

---

### Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID [^117YUP6D]. Therapeutic Advances in Gastroenterology (2024). Medium credibility.

The route of treatment, frequency of administration, related adverse events and the impact on the patient's quality of life may influence patient satisfaction with treatment. Treatment compliance, persistence and adherence are influenced by patient satisfaction with treatment. Shared decision-making is a process in which both patients and healthcare professionals are involved. This strategy is of considerable interest because it allows patients' preferences to be integrated into decision-making. – When several treatment options can have different effects on patients' quality of life, it makes sense to choose the best treatment option together with the patient. Their active participation in the decision-making process could improve the treatment's effectiveness.

Humira was originally formulated with a citrate buffer and administered at 50 mg/ml in a latex-containing device with a 27-gauge needle. Injection site reactions, including pain on injection, were described and led to a modification of the buffer formulation to eliminate certain excipients, notably citrate and citric acid, a reduction in the size of the needle and the elimination of latex, all of which are thought to be responsible for the pain. Larger volumes may cause pain at the injection site. The volume per injection has therefore been revised from 0.8 to 0.4 mL while continuing to deliver 40 mg per injection. By modifying Humira's formulation and injection device, pain on injection has been resolved. Biosimilars were first introduced in the early 2010s based on the demonstration of pharmacokinetics and clinical biosimilarity with an originator. In 2022, eight biosimilars were available on the French market. Some of the differences between all of the approved adalimumab biosimilars and reference product stem from their formulations and delivery device parameters. Amgevita, Amsparity, Hukyndra, Hulio, Humira and Yuflyma had all eliminated citrate buffers from their formulations. All adalimumab, except Amgevita, had removed latex in their delivery devices. Hukyndra, Humira and Yuflyma offered lower-volume options. Our results suggest that patients treated with an adalimumab formulation without citrate buffers, without latex and a reduced volume per injection had a higher satisfactory.

---

### Relationship between troponin on presentation and in-hospital mortality in patients with ST-Segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention [^11497wuF]. Journal of the American Heart Association (2019). Medium credibility.

Sources of Funding

This work was supported by the Blue Cross Blue Shield of Michigan and Blue Care Network as part of the Blue Cross Blue Shield of Michigan Value Partnerships program. The funding source supported data collection at each site and funded the data‐coordinating center, but had no role in study concept, interpretation of findings, or in the preparation, final approval, or decision to submit the manuscript. Dr Sukul was supported by a National Institutes of Health T32 postdoctoral research training grant (T32‐HL007853).

---

### Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA [^112V1XqQ]. Rheumatology (2017). Low credibility.

Objective

The aim was to assess the long-term safety and efficacy of certolizumab pegol over 4 years of continuous treatment in patients with axial spondyloarthritis (axSpA), including both AS and non-radiographic (nr-) axSpA.

Methods

RAPID-axSpA was a phase 3 randomized trial, double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204. Patients had a clinical diagnosis of axSpA, meeting Assessment of SpondyloArthritis international Society (ASAS) criteria, and had active disease. The assessed outcomes included ASAS20, ASAS40, AS DAS (ASDAS), BASDAI, BASFI and BASMI scores, along with selected measures of remission. Further patient-reported outcomes, peripheral arthritis, enthesitis, uveitis and quality-of-life measures are also reported.

Results

Two hundred and eighteen of 325 patients randomized (AS: 121; nr-axSpA: 97) received certolizumab pegol from week 0. Of these, 65% remained in the study at week 204 (AS: 67%; nr-axSpA: 63%). Across all outcomes, for AS and nr-axSpA, sustained improvements were observed to week 204 [week 204 overall axSpA: ASAS20: 54.1% (non-responder imputation); 83.7% (observed case, OC); ASAS40: 44.0% (non-responder imputation); 68.1% (OC); ASDAS inactive disease: 32.1% (last observation carried forward); 31.4% (OC)]. In the safety set (n = 315), there were 292.8 adverse events and 10.4 serious adverse events per 100 patient-years. No deaths were reported.

Conclusion

In the first study to evaluate the efficacy of an anti-TNF across both axSpA subpopulations, improvements in clinical and patient-reported outcomes at 24 and 96 weeks were sustained through 4 years of treatment, with no new safety signals.

Trial Registration

ClinicalTrials.gov, http://clinicaltrials.gov, NCT01087762.

---

### Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics [^111ufbRn]. Journal of the American Academy of Dermatology (2019). High credibility.

Restarting/resuming biologic treatment after discontinuation — loading-dose considerations: The necessity of repeating the loading doses upon restarting administration of the medication depends on the disease severity and how many doses were missed; consider repeating the loading doses upon restarting administration of the medication if the patient is flaring and/or if more than 3 to 4 half-lives have passed since the previous dose, and retreatment after discontinuation may result in a small percentage of patients not being able to recapture their previous robust level of response.

---

### Landscape of cardiovascular device registries in the United States [^114HCgPp]. Journal of the American Heart Association (2019). Medium credibility.

Regulatory oversight of innovative high‐risk medical devices attempts to clarify the benefit‐risk balance of the new technology using detailed premarket safety and effectiveness assessment, as well as continued oversight after approval. In the United States, the Food and Drug Administration (FDA) is responsible for both premarket and postmarket evaluation of medical devices, 1 but in recent months has taken a number of steps to truncate expectations for preapproval testing. 2, 3 These efforts will necessarily heighten the importance of rigorous postmarket surveillance systems designed to identify emerging safety signals, support comparative effectiveness evaluation, and refine product labeling.

Traditionally, postmarket surveillance of newly approved medical devices has relied heavily on passive collection of adverse events. Recognizing the limitations of this approach, however, the FDA's strategic vision for monitoring high‐risk devices increasingly emphasizes the role of medical device registries. A medical device registry is a database that actively collects and maintains information about individual patient exposures to medical devices. 4, 5 In the past decade, the FDA has leveraged its National Medical Device Registry Taskforce as well as the Medical Device Epidemiological Network experts to coordinate stakeholder input on registry objectives and development strategies. 6, 7, 8 Similarly, private initiatives through the Pew Charitable Trusts, Blue Cross Blue Shield Association, and the Brookings Institution have offered recommendations to anchor a national system for medical device postmarket surveillance on the routine establishment and use of registries. 9, 10, 11

While these working groups have focused on registry elements such as data quality and common definitions to promote data sharing, 12 other questions remain about the broad characteristics of medical device registries. For example, registry management can be led by professional societies, industry, academic institutions, and partnerships among these groups. These institutions may have different goals for the registries they oversee and varying rules and procedures for accessing registry data. Variations in registry implementation may have important ethical and practical implications for patients. For example, postmarket registries are commonly mandated by the FDA upon approval of novel medical devices. However, obligatory participation by patients as a condition of receiving a device may require heightened attention to informed consent and privacy protections.

To help understand the clinical and ethical challenges that may arise from greater regulatory and clinical reliance on medical device registries, we surveyed the current landscape of cardiovascular registries. We focused on registries' funding and stewardship, enrollment mechanisms, informed consent procedures, and access to data.

---

### Adalimumab [^113JpEXt]. FDA (2024). Medium credibility.

2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

The recommended subcutaneous dosage of Adalimumab-fkjp for adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg administered every other week. Methotrexate (MTX), other non-biologic DMARDS, glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with Adalimumab-fkjp. In the treatment of RA, some patients not taking concomitant MTX may derive additional benefit from increasing the dosage of Adalimumab-fkjp to 40 mg every week or 80 mg every other week.

2.2 Juvenile Idiopathic Arthritis

The recommended subcutaneous dosage of Adalimumab-fkjp for patients 2 years of age and older with polyarticular juvenile idiopathic arthritis (JIA) is based on weight as shown below. MTX, glucocorticoids, NSAIDs, and/or analgesics may be continued during treatment with Adalimumab-fkjp.

There is no dosage form for Adalimumab-fkjp that allows weight-based dosing for pediatric patients below 15 kg.

Adalimumab products have not been studied in patients with polyarticular JIA less than 2 years of age or in patients with a weight below 10 kg.

2.3 Crohn's Disease

Adults

The recommended subcutaneous dosage of Adalimumab-fkjp for adult patients with Crohn's disease (CD) is 160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) begin a dosage of 40 mg every other week. Aminosalicylates and/or corticosteroids may be continued during treatment with Adalimumab-fkjp. Azathioprine, 6-mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] or MTX may be continued during treatment with Adalimumab-fkjp if necessary.

Pediatrics

The recommended subcutaneous dosage of Adalimumab-fkjp for pediatric patients 6 years of age and older with Crohn's disease (CD) is based on body weight as shown below:

---

### White paper: American Gastroenterological Association position statement: the future of IBD care in the United States-Removing barriers and embracing opportunities [^111xEmYr]. Clinical Gastroenterology and Hepatology (2024). High credibility.

New models of inflammatory bowel disease (IBD) care delivery — To control cost and provide high-quality care to patients with IBD, payers, legislators, providers, and patients need to collaborate and innovate new models of care, and a system should reward highly functional multidisciplinary teams that manage IBD and provide high-quality, cost-effective care; proposed solutions include selectively reducing prior authorization barriers for reliable, consistent, evidence-based practice, which are being explored by advocates across the country, and nonprofit and patient advocacy organizations may expand their partnerships with health care industry leaders to bring practical solutions for patients. Examples include the partnership between the Crohn's and Colitis Foundation and Cost Plus Drugs, which resulted in the lowest cost available in the United States for an IBD biosimilar agent, and model partnerships, such as between SonarMD and Blue Cross Blue Shield of Illinois, that can help promote a proactive model that is both patient centered and cost saving; additionally, integrated models for proactive care and population management increasingly may be adopted as point-of-care technology and passive disease-monitoring strategies become more feasible, and it also may be feasible to expand the IBD medical home within the context of integrated insurer networks, with comprehensive care models similar to those at the University of Pittsburgh Medical Center and their integrated health plan.

---

### Length of anticoagulation in provoked venous thromboembolism: a multicenter study of how real-world practice mirrors guideline recommendations [^113BpcZ2]. Journal of the American Heart Association (2022). Medium credibility.

Sources of Funding

This study was supported by a short‐term biomedical research grant from the National Institutes of Health. The MAQI 2 collaborative is funded by the Blue Cross Blue Shield of Michigan/Blue Care Network.